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PREFACE 
 
For some individuals obtaining a PhD is for status, some for the ability to teach at 
the collegiate level, for others to fulfill a goal they set for themselves. For me this 
journey began with a quest for knowledge, for answers to many questions that all began 
one early morning on June 14, 2006. 
It was June 14, 2006, a morning I will never forget, and one that changed the 
direction of my life as well as my family’s lives forever. My nine year old daughter, who 
typically bounces down the stairs excited about going to school, practicing her dance 
steps from the previous night’s dance class, suddenly was struggling to walk. She 
managed to get herself to the breakfast table, but was unable to bring the spoon to her 
mouth. As we rushed her to the emergency room we quickly felt her slipping from us. 
Upon arrival to the ER she was unable to walk or talk to us. The grim diagnosis of viral 
encephalitis was given to us within a few hours. Over the next few days she continued 
to regress, unable to hold her head up, breathing and heart rate irregular, kidneys 
shutting down. The hospital staff graciously told us there was no reason to transfer her 
to ICU, nothing more could be done and keeping her on a pediatric floor allowed me to 
stay by her side. We watched her struggle to hold onto life for the next few weeks. Then 
came the reality of the brain damage. She survived; however, she was not the same 
child as before. Her mental and speech capacity was tested at an 18 month capacity, 
she was ataxic, hypotonic (low muscle tone), visually impaired, sensory and emotionally 
impaired. We were told she would be discharged from the hospital once the wheelchair 
she was fitted for arrived. I remember thinking, “Wheelchair? Why, my daughter will 
walk again.” However, reality soon hit when I began to care for a disabled child. We did 
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the traditional physical therapy, occupational therapy and speech and language therapy, 
but improvements were slow and minimal, and in many areas she regressed as seizure 
activity started and what little muscle done she had from the waist down diminished. 
I had joined some internet support groups and through that I heard about 
hyperbaric oxygen therapy. I had never even heard the term before, or remembered 
hearing it, but I knew it was something she had to try. Through a connection we had at 
Detroit Receiving Hospital, JeAnnah began treating in their hyperbaric oxygen therapy 
center on July 31, 2006. Prior to her starting I had every evaluation I knew of done, from 
OT to cognitive. I wanted to know beyond a mom’s feelings if she was really getting 
better.  
The evaluations were almost unnecessary. She immediately had huge gains, 
able to kneel after one treatment, after one week she no longer meet the criteria for 
occupational or speech therapy, she was mentally back to grade level, with no more 
seizure activity. Ten days later she stood with support, and two months later she was 
tap dancing.  
I was thrilled to have my little girl back, but it left a lot of questions in my mind. 
Could hyperbaric oxygen therapy help other special needs children? I have been 
teaching special needs children since 1985. I love that population of children, but what if 
there is something more than what we are offering in the schools to help them? Why did 
it bring my daughter back? Who else can it help?  
The population of autism was a group I had seen go from almost non-existent to 
common place on my case load as a teacher. I watched as some children appeared to 
progress very rapidly in a short burst of time, while others made almost no gains. Those 
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with the gains parents claimed they had found their answer in complementary therapies. 
Was there any validation to their claims? I related what I saw with my daughter to the 
child with autism. I had to know if and why it could help. With a yearning for answers I 
began to research complementary/alternative therapies and the efficacy behind them.  
With my yearning came answers, there is hope for recovery! There is more for a 
special needs child than the schools or traditional medicine can offer.  As an educator 
we need to be aware of what is available to help our children. 
Having a desire to help special needs children have access to complementary 
therapies I have founded a foundation, Oxford HBOT Kid’s Foundation. Not only do we 
offer funds for therapies for special needs children we have a future goal of offering an 
all-in-one center where they can go to have an array of therapies all at one location. 
With the center will now come the responsibility of more studies, and with the studies 
will come answers. Do these complementary therapies really offer hope, healing, 
recovery? We owe it to these children, to the families, to continue to seek out answers 
to the beguiling questions of why, how, and what if.  
This PhD, for me, is only the beginning, one piece of the puzzle put into place. 
There is so much more research to be done, so many more kids to help.  
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CHAPTER 1 
Introduction 
Background 
Autism is the fastest growing epidemic ever to occur with a prevalence of 1 in 80 
children by the age of 8 (MMWR/CDC, 2009). According to the Data Accountability 
Center (DAC) and the Center for Disease Control (CDC), Michigan reported in 1992 
1,180 cases of autism ages 6-22, by 2007 the number of reported cases went to 
10,803, and 12,166 for ages 3-22. Children ages 6-22 had an increase of 816%; in 
contrast, all other disabilities combined only went up 35%. To date these are the most 
current figures available. 
The costs of educating a child with autism are significant to the school systems 
and taxpayers as these children age and continue to increase in population. The CDC 
estimated the lifetime cost to care for an individual with autism to be 3.2 million dollars 
(Ganz, 2007). Below, the first graph exhibits the number of cases of autism from 1992-
2006, the second graph exhibits the percentage of increase.  
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Figure 1: Michigan cases of autism and all other disabilities  
 
Figure 2: 50 US states cases of autism and all other disabilities (CDC, 2008) 
Parents of autistic children who seek help are left with mixed messages between 
the medical and educational community (Carbone, 2010). Historically members of these 
two institutions do not work as a team with the parents to help the child, for the reason 
that identification policies have not been uniform (Stahmer, 2007; Filipek, Accardo, & 
Ashwal, 2000). One unique problem is a child may receive a medical diagnosis of 
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autism; however, the schools may not accept that as an educational diagnosis. 
Currently there is no medical test for diagnosing autism, requiring pediatricians who 
have had little to no training in autism to make a subjective diagnosis (Shah, 2001; 
Johnson & Myers, 2007). In order to receive a diagnosis in the schools of 
autism/autistically impaired a team consisting usually of five professionals, 
(psychologist, speech therapist, social worker, teacher, and special education teacher) 
most of who are trained in the evaluation of autism, conduct separate evaluations, next 
a consensus from the team is required in order to qualify a child as Autistically Impaired 
(Michigan Department of Education, 2004). Autism is the only condition that schools do 
not accept a medical diagnosis equivalent to an educational diagnosis; rather they must 
conduct a separate evaluation of their own due to the lack of specific guidelines in the 
medical community for diagnosing.  
 Consequently the mixed messages and lack of team work often encourages 
parents to seek out answers and treatments on their own, at times creating conflict 
between the schools and the parents (Scheuermann, Webber, Boutot, & Goodwin, 
2003).  Presumable, educating a child with autism can best be done when both the 
medical and educational community work together to educate themselves in what 
services and therapies are available along with the rationale behind the treatment.  
Among the many services and therapies available is hyperbaric oxygen therapy 
(Rossignol, D., Rossignol, L., James, Melnyk, & Mumper, 2007). This therapy, as with 
many of the others, uses medical research as rationale behind treating the child with 
autism and educational assessments to show outcomes. For this reason, hyperbaric 
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oxygen therapy should be further researched as a potential treatment to demonstrate 
the benefits to a child with autism in their educational environment.  
Public school personnel have been using what they refer to as best practice or 
evidenced-based curriculum/practices to educate children with autism, even though the 
research is not always favorable to the transferability of these skills or their success 
(Ganz, Simpson & Corbin-Newsome, 2008; White & Smith, 2002; Billstedt, Gillberg, C., 
& Gillberg, C., 2005). In conjunction with traditional academic curriculum, schools use 
three therapeutic interventions as part of the educational program: physical therapy, 
occupational therapy, and speech and language therapy. Although these programs are 
available to many parents through local therapy centers and paid for via their health 
insurance, the schools offer these services, sometimes with the requirement of a 
prescription and possible Medicaid reimbursement, to enhance the child’s educational 
output. As a result teachers are able to document the educational benefit of medical 
intervention in a school setting. 
Understanding the child's clinical and medical condition can play a key role in the 
educational success of the child. If a child does not feel well, educating them can be 
almost impossible as they are not in the mindset to focus on learning. Some areas, such 
as blood sugar levels with the diabetic child, are easier to understand and regulate. 
Educators recognized the correlation between focusing and the ability to learn, and 
proper blood sugar levels (Taras, Potts-Datema, 2005). Other areas, such as the 
gastrointestinal issues (GI) with the child with autism, are much more difficult to 
recognize and regulate (Rossignol et al., 2007). The discomfort a child experiences as a 
result of the GI issues often is expressed in anger outburst, self-abuse, or pulling away 
  5 
 
 
 
from others, hence affecting the ability to educate the child (Jepson, 2007). As a result, 
it is presumably valuable for a teacher of children with autism to be educated in the 
clinical scientific data and treatments of this condition and have the knowledge to 
increase the effectiveness of the child’s educational program by gaining an 
understanding off all clinical aspects and treatments.   
Beginning of autism  
 Kanner (1943) published an early work on autism followed by Asperger (1944). 
Kanner (1943) described the children as ones "whose condition differs so markedly and 
uniquely from anything reported so far" (Kanner, 1943). At that time, autism was 
identified in approximately four to five per 10,000 children. (Kanner, 1943) There was no 
significant increase in the identified cases of autisms after the publication of their works; 
rather they sought to locate children with those characteristics.  More recently, autism 
has shown an incredible growth, a growth faster and more globally spread than any 
other condition in history (Byrd, 2002). Today, according to the Center for Disease 
Control (CDC), autism is found in approximately 1 in 80 children with the prevalence 
four times more likely to occur in males versus females (CDC, 2009). 
Definition  
The guidelines for diagnosing autism are found in the Diagnosis and Statistical 
Manual of Mental Disorders (DSM). According to the CDC the autism diagnostic criteria 
first began in 1956 with the Kanner (1956) criteria. It stated the criteria as "Lack of 
effective contact; desire for sameness; fascination with objects; mutism or non-
communicative language before 30 months of age" (Kanner and Eisenberg 1956 p. 
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557). The previous versions DSM-I (1952) and DSM-II (1968) did not include autism; at 
that time the prevalence of autism was not prevalent enough to be included.  
 In 1978 the CDC accepted the Rutter criteria, which emphasized delayed and 
unusual social and language development and early onset of unusual behaviors (Rutter, 
1978). In 1980, autism was addressed in the DSM (third edition) for the first time. The 
DSM-III expanded the criteria to differentiate between schizophrenia and autism and 
introduced for the first time the concept of Persuasive Developmental Disorders (PDD).  
At that time autism was defined as infantile autism. In the 1987 version of DSM-IIIR the 
wording was revised to autistic disorder (Lord, Pickles, McLennan, Rutter, Bregman, 
Folstein…Minshew, 1997). The current version, DSM-IV (1994), includes qualitative 
deficits in the areas of social interaction, communication, repetitive or stereotype 
behaviors, interest or activities. The expansion also included a separate definition for 
Asperger’s Disorder, Rett’s Disorder, Childhood Disintegrative Disorder, and Pervasive 
Developmental Disorder Not Otherwise Specified (PDD-NOS), previously expanded 
through the ICD-10 (International Statistical Classification of Diseases and Related 
Health Problems, an international medical classification of diseases) in 1992. The 
expanded version of the DSM-IV introduced the definition of Persuasive Developmental 
Disorders, commonly referred to as ASD (Ozonoff, South & Miller, 2000).  
According to the Center for Disease Control (CDC, 2009), Autism Spectrum 
Disorder (ASD) is an umbrella of disorders of developmental disabilities identified by 
deficits in communication and social interactions; along with unusual, sometimes 
repetitive, behaviors; having areas of interest often with a narrow focus; and frequently 
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insistence on sameness. The cognitive abilities can vary from superior intelligence to 
mental impairment. ASD is found in all races, ethnic and socioeconomic levels.  
 The quest for increased educational outcomes for children with autism is a 
challenge that confronts educators of children with autism. Alternative therapies, such 
as diets, supplements, chelation, and hyperbaric oxygen therapy, are often 
characterized by cynicism, rather than as educational and medical innovations that 
require further empirical research. Even after several decades of experimenting with 
more traditional methodology, best practice yields poor outcomes (Billstedt, et al., 
2005), leaving educators to wonder what else is available. This was supported in a long-
term study of 120 children with autism (Billstedt, et al., 2005). In that study, fifty-seven 
percent of those studied showed very poor outcomes. (Poor outcome was defined as: 
not employed or engaged in education/vocational training, and not living independently. 
Good defined as employed or engaged in education/vocational training and living 
independently.) None had a good outcome. Teachers have tried implementation of long-
standing instructional methods and/or modernization of those techniques, with 
outcomes still not achieving desirable results. The implementation of 
alternative/complementary therapies has resulted in many parents feeling that it may be 
in conjunction with traditional school based methods and complementary therapies is 
where they will find the answer to enhance the learning capabilities of their child 
(Roylance & Cohn, 2011). Those parents are in agreement with Rimland, "Autism is 
treatable" (testimony of Bernard Rimland, Before House Committee on Government 
Reform, 2000). Hyperbaric oxygen therapy is one alternative therapy many parents are 
seeking.  
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Statement of Problem 
The outstanding question is whether hyperbaric oxygen therapy provides a 
measurable benefit to children with autism versus those who only receive traditional 
school-based instruction. This question will be addressed with an observational study of 
students who receive hyperbaric oxygen therapy using the Autism Treatment Evaluation 
Checklist (ATEC) as a measurement tool.  
The researcher will explore the relationship between the use of hyperbaric 
oxygen therapy and improvements in the child's language/communication, social 
interaction, and behaviors. To demonstrate the use of hyperbaric oxygen therapy on a 
child with autism the researcher will look at  
• the possible etiologies of autism,  
• the scientific research and history supporting these claims, and  
• what scientific research ascertains about the brain of an autistic child, and  
• how the above correlate to the use of hyperbaric oxygen therapy 
This information can help bring light to developing the best educational program for a 
child with autism.  
Research Questions 
1. Is there an increase in speech/language/communication of an autistic child who 
has received hyperbaric oxygen therapy using the Autism Treatment Evaluation 
Checklist as a measurement tool?  
2. Is there an increase in sociability of an autistic child who has received hyperbaric 
oxygen therapy using the Autism Treatment Evaluation Checklist as a 
measurement tool? 
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3. Is there an increase in sensory/cognitive awareness of an autistic child who has 
received hyperbaric oxygen therapy using the Autism Treatment Evaluation 
Checklist as a measurement tool? 
4. Is there an increase in the health/physical/behavior of an autistic child who has 
received hyperbaric oxygen therapy using the Autism Treatment Evaluation 
Checklist as a measurement tool? 
Rationale for study 
 Educators of children with autism continue to strive for ways to improve the 
education for these children. Complementary therapies, such as hyperbaric oxygen 
therapy, diet, vitamin/supplements, and chelation are increasing with popularity by the 
parents with little research as to the efficacy of these treatments and the correlation to 
the education of the child. The schools currently use speech and language therapy 
along with physical and occupation therapy, both of which are considered a medical 
intervention, for children with autism; however, evidential research for these, along with 
medical interventions are lacking. In order for educators and parents to know if 
complementary interventions, such as hyperbaric oxygen therapy work, research must 
be done. This paper will be presenting the data on clinical causes for this disease, the 
impact on the ability of the child to learn and the theory that hyperbaric oxygen therapy 
(HBOT) when used as an intervention can improve the educational and productive life 
of a student with autism. 
Hypotheses 
 The etiology of autism may be rooted in the environmental insult resulting in brain 
damage inflammation that manifests itself in the symptoms exemplified in autism. These 
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symptoms can be treated and lessened through hyperbaric oxygen therapy. It is the 
primary hypothesis that children who undergo hyperbaric oxygen therapy will show 
clinical improvements measured through the Autism Treatment Evaluation Checklist 
that will improve the education of the child with autism. 
Definition of terms 
abort: a dive/treatment that is stopped part way through 
alternative/complementary therapy: therapies/treatments that are not traditionally   
covered by insurance, and are seen as an additional to traditional covered 
treatments 
amygdale: part of the limbic system, almond-shaped clumps of cells deep in the brain, 
deals with response to danger, anxiety, and possible social interaction 
ascend: reduce atmospheric pressure 
ASD: Autism Spectrum Disorder 
ata: atmospheres absolute 
CDC: Center for Disease Control and Prevention 
cerebral hypoxia: impaired oxygen delivery 
chamber: a device used to increase atmospheric pressure that is filled with 100% 
medical grade oxygen 
descend: increase atmospheric pressure 
dive: individual hyperbaric oxygen therapy treatment 
FDA: Food and Drug Administration 
fMRI: functional Magnetic Resonance Imaging 
HBOT: hyperbaric oxygen therapy 
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hippocampus: short term memory and regulates emotions—includes gyrus, very 
sensitive to oxygen deprivation 
in vitro: procedures or research done outside of a living organism 
in vivo: procedures or research done inside a living organism, clinical trials are a form of 
in vivo 
microglia and astroglia: cells dealing with immune system and neurological tissues  
PDD-NOS: Pervasive Developmental Disorder, not otherwise specified 
SPECT scans: single photon emission computed tomography 
Limitations 
1. The small size of the study, 5 participants, will not show statistically significant 
outcomes; rather a trend of improvements will be assessed. 
2. Participation in the study is voluntary, thus findings may be reflective of those who 
exhibited a more positive attitude. 
3. Parents are required to transport their child to the hyperbaric clinic five times a week 
at their expense; therefore, it may lend itself to a higher social economic status.  
4. The study is limited to children with autism in the Metropolitan Detroit area. 
Hyperbaric Oxygen Therapy 
Hyperbaric Oxygen Therapy also called (HBOT), or in Europe High Density 
Oxygen Therapy (HDOT), is a specialized therapy administered by delivering one-
hundred percent oxygen to a patient through increased atmospheric pressure above 1.3 
atmospheres absolute (ata) in order to improve or correct health conditions.  The use of 
oxygen under pressure is considered drug therapy to treat a multitude of neurological 
and physical maladies, requiring a prescription from a physician (Gill & Bell, 2004). The 
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effects of hyperbaric oxygen therapy are based on the gas laws.  According to Henry’s 
Law of physics, by providing pure oxygen in a pressurized chamber a patient receives 
20-30 times more oxygen than is delivered at sea level or at normal atmospheric levels, 
saturating the body with oxygen. When a patient is in the chamber at 2.5 ATA the 
plasma carries and delivers as much oxygen to the tissues as do the red blood cells 
(Tibbles & Edelsberg, 1996). Of even greater importance to healing, the gradient 
between the plasma and red blood cells is so precipitous it drives a remarkable amount 
of oxygen far deeper into the oxygen poor tissue compared to normal conditions (Leach 
& Wilmshurst, 1998). Some of the effects are promotion of the growth of new capillaries, 
increased production of the body’s stem cells, decrease in swelling and inflammation, 
increase in the body’s ability to fight infections, clearing and deactivation of toxins and 
metabolic waste products from the body, and acceleration in the rate of healing (Marx, 
Ehler, Tayapongsak, & Pierce, 1990; Hunt, 1988; Knighton, Silver & Hunt, 1981, 
Knighton, Halliday & Hunt, 1984) These results change the cells and surrounding tissue 
significantly enhancing the body's ability to aid in its own healing.   
 There are two styles of medical devices that deliver this therapy, monoplace and 
multiplace chambers. The monoplace chamber is designed to hold one person. The 
patient lies on a gurney and is slid into a large eight foot acrylic chamber enclosed with 
steel ends. Once the patient is inside, the chamber is filled with one-hundred percent 
medical oxygen. The patient completes the treatment in 60-90 minutes; this is referred 
to as a “dive.” The multiplace chambers hold two to eighteen people. It is a large steel 
chamber, resembling a submarine. Inside the patients sit in chairs or lay down on a 
gurney. The chamber is filled with ambient air and pressurized the same as the 
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monoplace. The oxygen is administered through a device referred to as a “hood” that is 
worn over the head. Both chambers are pressurized according to the prescription, 
usually between 1.5ata to 2.4ata, for a duration of 60-90 minutes once a day for 40 
days, usually five times a week.  
 Hyperbaric oxygen therapy is not a new therapy. Henshaw (1662) first 
documented hyperbaric therapy in 1662 when he built his first hyperbaric chamber 
referred to as a domicilium.   Since then, hyperbaric therapy has been used around the 
world to successfully treat a wide variety of medical conditions (Gill & Bell, 2004). In 
1937 hyperbaric oxygen treatments were first used for decompression sickness 
(Yarbrough & Behnke, 1939), but it was not until 1955 that interest in hyperbaric 
medicine really expanded (Churchill-Davidson, Sanger, & Thomlinson, 1955). In 
Amsterdam the next year, Dr. Boerema reported that hyperbaric oxygen therapy was a 
therapeutic aid in cardiopulmonary surgery (Boerema, Kroll, Meijne, Lokin, Kroon, & 
Huiskes, 1956). Shortly after his colleague's discovery, W.H. Brummelkamp, published 
a discovery of his own, that anaerobic infections were inhibited by hyperbaric therapy 
(Brummelkamp, Hogenijk, & Boerema, 1961). International interest was rekindled in 
1962 when reports of the enormous benefits of hyperbaric oxygen therapy in the 
treatment of carbon monoxide poisoning were published (Smith & Sharp, 1962). These 
discoveries, and more, pushed hyperbaric medicine into the modern era. Today, one of 
the most common uses is for diabetic wounds (Gill & Bell, 2004).  Installations of 
hyperbaric units quickly began at some of the most revered and prestigious medical 
centers in the United States. A few of these early adopters were Harvard Children's 
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Hospital, New York Sinai Hospital, Duke University, and Good Samaritan Hospital in 
Los Angeles. 
 The wide variety of use in hyperbaric medicine is best understood by examining 
the body’s reaction to injury. When the body sustains an injury of any kind, from ankle 
sprains, lacerations, cardiac arrest to near drowning, lightning strikes or complications 
at birth, the bodies activates the inflammatory reaction. This reaction is both fast and 
dramatic, with positive along with negative results. During the initial injury the body 
brings all its necessary resources, including toxic chemicals and digestive enzymes, to 
the injury (Munford and Pugin, 2001). In a sense, this cleans up the mess; however, in 
the process a scar is formed (Desmouliere, Redard, Darby & Gabbiani, 1995). The body 
can tolerate low oxygen levels fairly well, but it cannot tolerate low blood flow. The white 
blood cells that have come to the injury can create a blockage in the vessel, reducing 
blood flow. This is tolerable when it is a non-crush wound or a sprain, but when this 
occurs in an organ such as the brain or heart, the inflammation can be devastating 
(McGeer, 1995). Current research suggests that high pressure oxygen delivered within 
two to three hours after injury may prevent or minimize the damage (Yeo, McKenzie, 
Hindwood & Kidman, 1976).  However, improvements have been shown up to fourteen 
years later with neurological conditions treated in 100% oxygen in hyperbarics (Harch & 
McCullough, 2007). This same concept can be applied to a child with autism in relation 
to the inflammation associated with the condition. Below are some pictures to clarify. 
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Normal Blood Flow 
 
 
Figure 3: 
Ambient air has approximately 21% oxygen. The red blood cells, carried by the plasma, 
distribute oxygen into surrounding tissue.  
 
Restricted Blood Flow 
 
 
Figure 4: If the blood vessel has a restriction, the red blood cells no longer can travel, 
therefore oxygen cannot reach the tissue. The blockage and lack of blood flow causes 
inflammation, leading to hypoxia (lack of oxygen). 
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Hyperbaric Oxygenation 
 
 
 Figure 5: 
While breathing 100% oxygen under pressure the plasma is saturated with oxygen. The 
plasma is then able to travel where the red blood cells cannot, bringing oxygen to the 
hypoxic tissue. 
 
 
Blood Vessel Regeneration 
 
Figure 6: 
The increased atmospheric pressure combined with 100% oxygen creates angiogenesis 
(new capillaries) and extended the length of the current capillaries, allowing the body to 
begin the healing process. (www.hyperbaricworx.com.au/whatis.aspx) 
 
Hyperbaric oxygen therapy has only been used under physician supervision for 
children with autism for a little over four years (Rossignol et al., 2007). Hence, new 
research is constantly coming out reporting the benefits of hyperbaric oxygen therapy 
with these children. There are multiple studies currently being conducted throughout the 
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United States. To understand the reason hyperbaric oxygen therapy works for children 
with autism, it is necessary to review some of the current research of the medical 
conditions of children with autism.  
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 CHAPTER 2 
Literature Review 
 In order to achieve best educational outcomes for children with autism, and to 
understand why complementary therapies could achieve favorable results, it is essential 
the etiology of autism be explored. Achieving improvements in the behavior, social, and 
speech deficits with these students can best be accomplished with an understanding of 
the etiology and its implication, hence overcoming educational deficits. One must look at 
the common explanations for the growth in number of students with autism, and then 
explore the history, and research on the subject of those claims. One philosophy of 
growth would be a simple misdiagnosis; in other words, the number of autistics has 
always been there, however the children were labeled differently. Another common 
explanation is environmental toxins, often narrowed down to mercury or viral overload. 
One last school of thought, the cause of autism may be linked directly or indirectly to 
genetics.  
Etiology: misdiagnosis 
 One explanation sometimes given for the rapid growth of autism is a previous 
misdiagnosis (King & Bearman, 2009).  Believers in this theory feel, for the most part, 
the number of children with autism has not changed, rather the child’s diagnostic label 
has changed. According to this viewpoint these children have been misdiagnosed with 
mental retardation, health impaired, or cerebral palsy, etc. However, if this were the 
case one would expect to see a correlation with a proportional reduction in numbers of 
other disabilities, such as mental retardation, health impaired or physically impaired, as 
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autism increases. The state of California, due to a statewide education system, has 
clear records of the numbers of students with disabilities. In 2002 a comprehensive 
randomized study was conducted at the M.I.N.D. Institute (Medical Investigation of 
Neurodevelopmental Disorders) to investigate possible explanations as to the increase 
in the number of children with autism, and if there really was an increase in the number 
of children with autism. They compared two groups; the first group was born between 
1983-1985 the second group was between 1993-1995. The Principal Investigator in the 
study, Byrd stated in an interview with the Los Angeles Times, "The results of this study 
are, without a doubt, sobering" (Maugh, 2002). In the published report Byrd 
summarizes, "The unprecedented increase in autism in California is real and cannot be 
explained away by artificial factors, such as misclassification and criteria changes, 
according to the results of a large statewide epidemiological study."  He also stated, 
"The observed increase in autism cases cannot be explained by a loosening in the 
criteria used to make the diagnosis (Byrd, 2002 p. 5) The study did not include persons 
with Pervasive Developmental Disorder (PDD), PDD-Not Otherwise Specified (PDD-
NOS), Asperger's Syndrome, or any of the other milder autism spectrum disorders. The 
California data reflect only those children who have received a professional diagnosis of 
level one, DSM IV autism - the most severe form of autism.  
 Below is a graph tallying the number of students in the state of California from 
1994 to 2002. As shown in Figure 3, the number of students with autism is rapidly 
increasing; however there is also small increase in the other disabilities that is about 2-
3% (Byrd, 2002 p. 8-9). A more current study cites statistics from 1987-2007. In respect 
to autism there is over 1,100 percent increase in autism over two decades while the 
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other disabilities increased 136 percent. (California Health and Human Service Agency, 
2007, p. 10) 
Figure 7 - Percent Change in All Disabilities from 1994 through 
2002
 
Legend defined:  
AUT = autism, CP = Cerebral Palsy, MR = Mental Retardation, EP = Epilepsy.  
(California Health and Human Service Agency, 2003, p. 7) 
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In Table 1 below, continuing the data with the percentage of growth from 1987 to 2002. 
The statistics in the chart are similar to the graph. 
Table 1 - Percent Increase in All Diagnostic Populations from 1987 to 2002 and from 
1998 through 2002 
 Dec. 87 Dec. 02 % change Dec. 98 Dec. 02 % 
change 
Persons with autism  2,778 20,377 633.51% 10,360 20,377 96.69% 
Persons with Mental 
Retardation 
72,987 130,722 79.10% 108,563 130,722 20.41% 
Persons with Epilepsy 22,683 35,689 57.34% 30.656 35,689 16.42% 
Persons with Cerebral 
Palsy 
19,972 33,071 65.59% 28,529 33,071 15.92% 
Total Population with 
CDER’s 
80,389 163,792 103.75% 129,169 163,792 26.80% 
 
 Note: Some individuals have more than one of the above diagnoses and are therefore 
counted in multiple categories  (M.I.N.D. 2003). 
(California Health and Human Service Agency, 2003, p. 8) 
 
 
Figure 8 – Percentage of increase in autism v. all other disabilities  
U.S. Department of Education from 1993-2003  
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The table below gives the exact percentages for the above graph. 
Table 2. Percentages of increase in autism v. all other disabilities 
YEAR ALL OTHER DIABILITIES AUTISM 
1993 3% 23% 
1994% 6% 45% 
1995 10% 87% 
1996 13% 121% 
1997 17% 173% 
1998 20% 247% 
1999 23% 324% 
2000 25% 411% 
2001 27% 533% 
2002 29% 662% 
2003 31% 805% 
(US Department of Education, 2004) 
 
As evident by the statistics in California and the U.S. Department of Education, 
the number of students with autism has had a significant percentage of increase. If the 
explanation of the enormous significant in the percentage of students with autism is 
nothing more than a re-diagnosing or misdiagnosing, the percentage of increase would 
have to remain relatively proportional with other disabilities decreasing, particularly in 
the area of Health Impaired and Mental Retardation. The graph illustrates the 
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percentage of increase in autism from 1987 to 2002 increased by 633.51% and in 1998 
to 2002 increased by 96.69%. All other disabilities also increased; however, at a much 
smaller and more acceptable rate in concurrence with the population increase. Hence, 
the explanation of misdiagnosis statistically is not evident. 
Etiology: Toxic Insult History 
  Another explanation, although often viewed as controversial, relates to 
vaccinations. There are three facets of concerns regarding vaccines: thimerosal 
(mercury), overtaxing the body with live viruses that contain viral contaminants (viral 
overload), and demyelination (Halsey & Hyman, 2001; Harrington, Patrick, Edwards, & 
Brand, 2006.). The most common school of concern is thimerosal, a mercury component 
added to childhood vaccines in the 1930’s (Geier, et al., 2004). The proportional 
increase in autism with the increase in recommended vaccines, along with the 
coinciding identification of autism in the late 1930's with the beginning of thimerosal's 
use is one reason for the popular controversy (Burton, 2003). Therefore, a closer look at 
the history of thimerosal is warranted.  
Vaccines and Thimerosal  
Thimerosal is made basically of two compounds, ethylmercury and thiosalicylic 
acid. Thimerosal is 49.6% mercury by weight and releases ethylmercury as a metabolite 
(Clarkston & Magos, 2003). Once in the body ethylmercury is converted to inorganic 
mercury which preferentially accumulates in the brain and kidney (Baskin, Ngo, & 
Didenko, 2003). Essentially it is a manmade organic form of mercury, which converts to 
an inorganic form, with a preference for nerve cells, although it is known to freely travel 
through the body. When thimerosal enters the nerve cell it becomes tightly bound, 
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accumulating there for years. (Geier, et al., 2004; Baskin, Ngo, & Didenko, 2003). The 
theory is this can cause permanent degeneration of brain cells, with unpredictable 
damage. Mercury also is bio-accumulative in living things, in humans it is stored in fat 
cells that persists for many years (Clarkston & Magos, 2003). Ethylmercury can 
significantly increase the concentration of inorganic mercury in many organs (Magos, 
Brown, Sparrow, Bailey, Snowden, & Skipp 1985).  
Thimerosal was developed by Dr. Morris Selig Kharasch, a chemist and fellow at 
Eli Lilly Pharmaceutical Company, on June 27, 1927; on June 5, 1928 Thimerosal was 
patented by Dr. Kharasch (Burton, 2003). (U.S. Patent 1,672,615 “alkyl mercuric 
sulphur compound and process of producing it.”)  
 In 1929 an outbreak of meningitis was causing many deaths. Dr. Smithburn was 
treating patients with meningitis unsuccessfully. After being told of a cure by Eli Lilly 
Pharmaceutical Company, and with no other options, he experimented by injecting 
twenty-two patients who were dying of meningitis with thimerosal,, not to examine the 
toxicology of thimerosal but rather, in desperation for a cure. The use of the thimerosal 
was published as a study by Powell and Jamieson (1931) using information provided by 
Dr. Smithburn. Powell and Jamieson (1931) stated, “It did not appear, however, to have 
any deleterious action when used in rather large doses intravenously when all the drug 
entered the vein” (p. 306). They failed to note significant information regarding the 
study, such as why one-third of the patients were only studied for one day due to death 
within 24 hours. Two of the patients developed phlebitis or sloughing of the skin, the 
breakdown of the skin itself. (Geier, et al., 2007). This study has been used for years as 
evidence for the safety of thimerosal until 2002. The specific clinical assessments were 
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not described and no laboratory studies were reported, the only stated report was that 
all of the patients died from the meningitis. Although the thimerosal was given in 
significantly larger amounts than children receive today, it is relevant that this is the only 
testing done on the thimerosal prior to its general use in vaccines. 
A press release on March 17, 2002 revealed that during a discovery process in 
the case of Ounter v. Eli Lilly and Company, et al, that Eli Lilly & Company knew as 
early as 1930 of the dangers of thimerosal. At that time the study was fully disclosed 
and the outcome of death was exposed, but more importantly the study from Dr. 
Smithburn, Powell, and Jamieson on the meningitis patients could no longer be used as 
evidence of the safety of thimerosal.   
 On October 1929, Eli Lilly and Company registered thimerosal under the trade 
name Merthiolate. Thimerosal was first introduced into vaccines due to the need to 
reduce bacteria, as this was prior to the time of antibiotics (penicillin was first 
manufactured in 1942 as a response to streptococcal septicemia) and the injections 
were often given by general practitioners drawing vaccines from multi-dose vials in 
unsanitary conditions, however, the efficacy of its antibacterial properties has not been 
properly tested, and has been disputed (Burton, 2003). In 1935, with the growing 
concern of staphylococcus, a study was conducted to assess the efficacy of thimerosal 
killing the bacteria on chick tissue. Although the study was conducted in the 
Netherlands, they used the FDA phenol coefficient method, which was the method 
accepted by the US FDA at the time to examine and rate disinfectants. The results of 
the study determined the thimerosal was thirty five times more toxic to the heart tissue it 
was meant to protect, than the bacteria it was meant to kill (Salle, 1961).  
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 On July 22, 1935 Jamieson, Director of Biological Division for Eli Lilly, received a 
letter from Pittman-Moore, an animal vaccine manufacturer, sent to inform Eli Lilly of 
their research with Thimerosal in vaccines for dogs. The letter stated,  
“We have obtained marked local reaction in about 50 percent of the dogs injected with 
serum containing dilutions of Merthiolate varying from 1 in 40,000 to 1 in 5,000, and we 
have demonstrated conclusively that there is no connection between the lot of serum 
and the reaction. In other words, Merthiolate is unsatisfactory as a preservative for 
serum intended for use on dogs. I might say that we have tested Merthiolate on humans 
and find that it gives a more marked local reaction than does phenol and tricresol."  
Pittman-Moore pronounced Thimerosal “unsatisfactory as a preservative for serum 
intended for use on dogs” (letter, 1935).  
 
 About the same time, two doctors, Kanner and Asperger, both begin observing a 
newly discovered neurological disorder found in children. Kanner's (1943) first child 
studied began September 1931; the same year thimerosal was used in the vaccines. He 
described the children as ones "whose condition differs so markedly and uniquely from 
anything reported so far" (p. 217). Kanner was at John Hopkins University in Baltimore 
and Asperger was in Vienna, Austria-Hungary. Asperger’s works were not known in the 
United States until a British researcher published his findings in 1981 (Wing, 1981).  
 The FDA’s regulation of drugs did not have influence at the time of the 
introduction of Merthiolate (thimerosal) to stop the manufacturing; it was not until 1938 
that the FDA began to have the power to regulate drugs marketed in the United States 
under the Food, Drug, and Cosmetic Act of 1938. Drugs manufactured prior to 1938 
were almost all grandfathered in as being safe, devoid of safety or efficacy testing 
(Swann, 1998). To date, the FDA does not do any testing of any drugs. They rely solely 
on the test done by the manufacturer with the data presented to them.   
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In the 1940’s children began receiving the DTP (Diphtheria, Tetanus, and 
Pertussis) and smallpox vaccines. The DTP and Tetanus vaccines contained thimerosal 
at twenty-five micrograms of mercury per shot. The DTP was the only mercury 
containing vaccine routinely given to young children (Burton 2003).  Of interest, the FDA 
does not require the manufacture to test the DTP in combination; rather it accepts 
testing done by individually giving Diptheria, Tetanus, and Pertussis, as with the MMR. 
This is according to World Health Organization standards (WHO, 1979).  
In 1967, Nelson and Gottshall published their study on the effects of Merthiolate 
(thimerosal) in relation to the Pertussis vaccine,  
“Pertussis vaccines preserved with 0.01% Merthiolate are more toxic for mice than 
unpreserved vaccines prepared with the same parent concentrate and containing the 
same number of organisms...An increase in mortality was observed when Merthiolate 
was injected separately, before or after an unpreserved saline suspension of pertussis 
vaccine"  (Nelson & Gottshall, 1967, p. 590). 
  
Their research showed thimerosal killed mice when injected with a vaccine of pertussis. 
Interestingly, the time of death for the mice did not correspond with the amount of 
mercury; rather death occurred in all amounts tested.  “The toxicity in mice of final lots 
of preserved vaccine prepared from concentrated vaccines which were atoxic or only 
slightly toxic has been observed in other laboratories and has been the source of much 
speculation” (p. 593). In response to the latest publications, the Medical/Science 
Department of Eli Lilly & Company requests that the claim "non-toxic" on thimerosal 
labels be deleted in the next printing run. The label for Eli Lilly & Company's Thimerosal 
changed to "non-irritating to body tissues" and non-toxic was omitted.  
 The following year in 1968 the Rho-GAM is introduced as a shot given to women 
who are Rh-Negative. The shot is to be given right after giving birth, later to be added at 
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twenty-eight weeks of pregnancy. The shot contains ten point five micrograms of 
mercury from thimerosal, absorbable through the mother's breast milk and to the fetus 
(Grigg, 2004; www.atsdr.cdc.gov; James, Slikker, Melnyk, New, Pogribna, & Jernigan, 
2005). 
In 1971, the Measles, Mumps and Rubella (MMR) vaccine was introduced. At 
this time only the DTP, MMR and Polio vaccines were being given to children. The DTP 
at that time was the only vaccine that contained thimerosal at 25 micrograms of mercury 
per shot. The MMR and Polio vaccines were both live virus vaccines. Routine smallpox 
vaccination ceased.  The same year Bay-Rho, by Bayer Corporation, was introduced for 
women who are Rh-Negative. The shot is to be given directly after giving birth. Bay-Rho 
contained 35 micrograms of mercury from thimerosal.   
Axton (1972) published an article on mercury poisoning. The symptoms and 
course of the six patients suggested mercury poisoning. Axton stated, "In chronic 
poisoning, where small amounts of mercury are ingested over a long period of time 
symptoms are mainly neurological." The quick death in these patients, "suggests that 
the mercury compounds produced by the degradation of Merthiolate [thimerosal] were 
in a non-chelatable form" (p.421 ). 
 In 1977 thimerosal was used as a preservative in antiseptic wipes at the Hospital 
for Sick Children in Toronto on infants for umbilical cord care. As a result ten infants 
died from "mercury intoxication" and many others reported to have "Pink Disease." 
(Amin-Zaki, Elhassani, Majeed, Clarkson, Doherty, & Greenwood, 1974). The 
researchers reported, "four infants exposed postnatally did not exhibit signs or 
symptoms, though their blood levels were >1000ppb, and one was >1500ppb. This 
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remarkable phenomenon is not easily explained, although part of the answer may lie in 
the difficulty of assessing neurological function in this group" (p. 83). The researchers 
also document one survivor they traced for several years. At ten years of age he did not 
show visual field narrowing or numbness, as the researchers expected; however, the 
school reported that he was restless, easily distracted, and not interested in schoolwork, 
much like an Attention Deficit Disorder child of today. The wipes were later 
discontinued. However, it was not until 1982 that the FDA determined thimerosal to be 
toxic to cells and banned its use in over-the-counter drugs (Kirby, 2005).  
 The dangers of thimerosal were not only being explored in the use of vaccines, 
but in topical ointments as well. There were many documented concerns about the 
effects from topical use (Fagan, Pritchard, Clarkson & Greenwood, 1977); however, one 
clearly correlates with the vaccines. In 1973 in the files of Eli Lilly is an article entitled, 
"Dangers of Skin Burns from Thimerosal" which reported the case of a woman who 
received severe burns resulting from a chemical interaction between thimerosal and 
aluminum. The article suggested that thimerosal and aluminum should not be used 
together (Burton 2003; Fiasco 2002). Eli Lilly did add to their labels, “Do not use when 
aluminum may come in contact with treated skin."  However, thimerosal and aluminum 
continued to be used together in the DTP and DTaP vaccines for years and today are 
combined in the flu vaccine. In 1974 Eli Lilly stopped their production of vaccines; 
however they continue to produce thimerosal until 1991 with licensing agreements 
giving them profitability until at least 2010 (patent, 1,672,615). 
 Murkhtarova (1977) conducted a study in Russia. The findings suggested adults 
with neuropathology were in correlation to their exposure to low doses of ethylmercury. 
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It must be noted that, at this time, this concentration was at a much lower dose than 
what American children were receiving at the time in the vaccines.  
"The pathology of the nervous system presented certain peculiarities by comparison 
with the early period. In evidence were changes in the sympatico-adrenal system 
function, vascular lesions of the brain after the type of transient derangements of the 
cerebral circulation in the vertebro-basilar basin and angiospasms, diffuse changes in 
the nervous system with the predominant involvement of the hypothalamic cerebral 
structures and in some cases psychic disturbances were on record" (p. 4). 
 
 January 5, 1982 the Hepatitis-B vaccine containing thimerosal was initiated for 
adults who were at high risk of contracting Hepatitis B, i.e., IV drug users, prostitutes, 
etc. The same year the Swedish did a study of sensitivity to thimerosal, their findings 
revealed sensitivity in 10% of school children, 18% of twins, 16% military recruits, and 
26% of medical students (Burton 2003). NBC (1982) aired a documentary entitled, 
"DTP: Vaccine Roulette" presenting the risks related to the DTP vaccine. The response 
was vaccine manufactures and physicians lobbying the United States Congress to 
establish legislation to protect them against lawsuits from vaccine injuries. Parents of 
vaccine-injured children fought for safety provisions to be presented into the legislation 
that would require mandatory physician reporting and record keeping of vaccine 
reactions.  
 Kravchenko, Sovetova, & Chebotareva (1982), of the State Research Institute of 
Standardization and Control of Medical and Biological Pharmaceuticals at the Ministry 
of Health in Moscow, published his study on the DTP vaccine. He stated, "The 
components of B. pertussis antigens and thimerosal solutions have been found to 
produce the most pronounced cytotoxic effect on cells" ( p. 54). 
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 In 1983 Clinical Toxicology of Commercial Products, 5th edition referred to ethyl 
mercury as, "ethyl mercury derivatives are virulent neurotoxins on either acute or 
chronic exposure. They are especially hazardous because of their volatility, their ability 
to penetrate epithelial and blood-brain barriers and their persistence in vivo" (Gosselin, 
1984, p. III-270, p. II-136, p. III-266-7). 
 In March 1983, Kravchenko again published concerns of thimerosal's use,  
 
"The toxic action of preparations kills and damages the cells at the site of injection, thus 
inducing the formation of autoantigens whose effect on the body cannot be predicted. 
Thimerosal, commonly used as a preservative, has been found not only to render its 
primary toxic effect, but also capable of changing properties of cells. This fact suggests 
that the use of Thimerosal for the preservation of medical biological preparations, 
especially those intended for children, is inadmissible" (Kravchenko, Dzagurov, & 
Chervonskaia, 1983, p. 87).  
 
In another paper he stated, the concentration of thimerosal in just one 
vaccination was found to be enough to damage cells. He concluded, "Methiolate usage 
(thimerosal) for medical and biological preservation should be discontinued due to its 
high toxicity"  (Kravchenko, Chervonskaia, & Mironova, 1986 p. 490). Three years from 
when his original study was published Magos, et al (1985) came out comparing the 
toxicology of ethyl and methyl mercury. The results were stated, "There was little 
difference in the neurotoxicities of methlymercury and ethylmercury when effects on the 
dorsal root ganglia or coordination disorders were compared." The researchers also 
stated, "The neurological signs and symptoms of methyl and ethyl mercury intoxication 
are identical" (p. 263). Magos suggested one reason may be due to the fact that the 
dorsal root ganglia does not have the same protective blood brain barrier that the rest of 
the brain has (Magos, 2001). Magos often references Powell and Jamison’s 1931 study 
as evidence to the safety of thimerosal, however, does not note that Powell and 
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Jamieson’s study was shown in 1931 omitted evidence and distorted their data. (Geier 
et al., 2007) 
 In 1985 the HiB (Haemophilus Influenzae Type B) vaccine is licensed and 
included on the vaccine schedule to be given three times in the first six months of life 
and once more by the age of two years. The vaccine contains 25 micrograms of 
thimerosal per shot. However, it is only recommended to "high risk" population, in 1991 
the recommendation changed, it is added for all children. (CDC) 
 The following year, on November 14, 1986, Congress passes a Bill called, "The 
National Childhood Vaccine Injury Compensation Act" establishing a no fault 
compensation system for children injured by vaccinations. President Reagan signed 
Public Law 99-660 into effect.  Parents could no longer sue vaccine manufactures and 
would have to go through the Federal government instead. Now the government would 
be responsible for paying for a child of vaccine injury or death instead of the 
manufacturers. This is done through the Vaccine Injury Compensation Program (VICP) 
which was established in 1987. Money is collected as a fee for each vaccine given in 
order to establish capital to cover damage as a result of the vaccines. Physicians and 
vaccine manufacturers are no longer liable for any injury or death caused to a child who 
received a vaccine (Public Law 99-660). 
 The same year the CDC recommended the recombinant Hepatitis B vaccine to 
be given within hours of birth plus two more times before the age of six months. They 
also recommended the Haemophilus Influenzae Type B vaccine to be added to the 
childhood vaccination schedule. The cumulative amount of ethylmercury that children 
were now being exposed to nearly tripled. This exceeded the FDA's more relaxed 
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maximum threshold of 0.4 micrograms per kilogram of body weight (FDA; U.S. 
Enviornmental Protection Agency). Each shot contains thimerosal with 12.5 micrograms 
of mercury, totaling 187.5 micrograms of mercury by the age of six months. Hence, by 
twenty-four months of life, if all thimerosal containing vaccines were received, a child 
would have been given 237.5 micrograms of mercury. The average weight for a two 
year old child is 12.9 kg (28.4 pounds), making the acceptable dose 5.16 micrograms in 
contrast to the 237.5 micrograms they are receiving. This is 232.34 micrograms more 
than the recommended dose, approximately 45 times more than the FDA's maximum 
limit.  At the same time the U.S. Environmental Protection Agency (EPA) sets, still in 
effect today, the maximum safe level of exposure to mercury at .1mcg per kilogram per 
day. With these numbers in mind, at the day of birth an infant who receives the required 
Hepatitis B vaccine within hours of birth receives 12 micrograms, thirty times the EPA’s 
set safe level. At four months the same infant is required to get the DTaP and 
Haemophilus Influenzae Type B containing together 50 micrograms of mercury, six 
times the EPA’s set safe level. These numbers continue to increase. The same 
influenza vaccine given to an infant is given to an adult. According to the safety 
standards the infant would be required to weigh 330 pounds.  
 Kravchenko (1986), along with his colleagues continued to publish concerns 
regarding the dangers of Merthiolate (thimerosal). His research stated, "Merthiolate had 
the strongest irreversible lethal effect" (p. 491). He continued stating, “Merthiolate is 
toxic in a dose of 0.8 micrograms/ml" (p. 491). At this time most vaccines had 25 
micrograms of mercury, except the Hepatitis B which contained 12.5, much higher than 
the safety limits recommended by Kravchenko. The Russians and Japanese by this 
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time had complied numerous studies on the dangers of Merthiolate; these studies were 
published in English and available through PubMed. At this time the Institute of 
Medicine (IOM), CDC, FDA, American Academy of Pediatrics (AAP) always would 
clarify any of their reviews on thimerosal by stating no conclusive evidence is available 
on studies in English, disregarding the Japanese and Russian studies (Stratton, Wilson, 
McCormick, 2002).  
 In 1990 the CDC began recommending to all Rh-negative mothers Rho-Gam or 
BayRho during pregnancy as well as directly after the birth. At times more shots are to 
be given due to "complications". Rho-Gam contains 10.5 micrograms of thimerosal per 
shot; Bay-Rho contains 35 micrograms per shot. The same year the CDC began 
recommending a second Hib vaccine to all children at fifteen months, both containing 25 
micrograms of thimerosal. The CDC established The Vaccine Adverse Event Reporting 
System (VAERS) to monitor the safety of vaccines. However, the reporting system is 
voluntary and the CDC estimates less than 10% of actual adverse reactions seen with 
vaccines are reported by physicians or parents (CDC).  
 In 1991 it was noted that children born beginning in 1988 to 1991 show a 
significant jump in autism rates (Bradstreet, 2001). Other disabilities such as Attention 
Deficit Disorder, Attention Deficit Hyperactivity Disorder, Speech and Language 
Disorders, Behavioral and Emotional Disorders and others also begin to jump, along 
with Juvenile Diabetes, asthma and allergies.  
The Institute of Medicine (IOM) was asked to evaluate the science on a possible 
connection between vaccines and autism. In 1991 IOM published Adverse Effects of 
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Pertussis and Rubella Vaccines and confirmed that pertussis and rubella vaccines can 
cause brain and immune system damage. The researchers concluded the study with,  
"The committee found many gaps and limitations in knowledge bearing directly and 
indirectly on the safety of vaccines. Such shortcomings relate, for example, to 
pathologic mechanisms of specific infectious agents, the molecular basis of vaccine 
injury, and the natural history of conditions such as encephalopathy, mental retardation, 
and chronic arthritis. Although the committee was not charged with, and has not 
attempted, full consideration of the kinds of studies that would be both ethical and 
especially informative, either in the areas of vaccines that it has been charged to study 
or more generally it recognizes, nevertheless, that opportunities may exist for 
informative experiments in human populations that take advantage of the possibility of 
using alternative schedules for administration of vaccines. The availability and 
introduction of new forms of pertussis vaccine, for example, could offer valuable 
opportunities for comparison of vaccine safety as well as efficacy” (Institute of Medicine 
(U.S.). Committee to Review the Adverse Consequences of Pertussis and Rubella 
Vaccines., Howson, Howe, & Fineberg, 1991, p. 206).  
 
 The same year under the Carter administration, a national campaign to vaccinate 
all children with all CDC recommended vaccines by the age of two begins. "Every Child 
By Two (ECBT)," co-founded by former First Lady Rosalyn Carter and Better Bumpers, 
funded in part by Merck, Lederle, and Connaught pharmaceutical companies who are 
all major vaccine manufactures. (ecbt.org) 
 In the spring of 1991, Dr. Maurice Hilleman, vaccinologist, also senior Vice 
President of Merck, sent an internal memo to CEO Dr. Gordon Douglas, head of 
Merck's Vaccine Division, stating a panel of vaccine experts at Merck had serious 
concerns regarding the recommended changes in the Childhood Vaccine Schedule. 
Their concern revolved around the high doses of mercury to infants. The memo 
specifically stated the babies would receive 89 times the legal acceptable limit of 
mercury exposure. Their recommendation was to remove thimerosal from the vaccines. 
Merck did not remove the thimerosal (Levin, 2005). 
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 In 1991, manufactures of animal vaccines were banned from using thimerosal 
(Rock, 2004); in contrast that same year the CDC recommended infants be injected with 
a series of vaccines containing thimerosal. Their recommendation is that within twenty-
four hours of birth newborns should be vaccinated for hepatitis B (HepB), and two-
month-old infants should be vaccinated for haemophilus influenzae B (HiB) and 
diphtheria-tetanus-pertussis (DTP). All contain thimerosal, which increased the 
exposure 150%. Prior to 1989, preschoolers living in the U.S. were recommended to 
receive eleven vaccinations (some in multiples): polio, diphtheria-tetanus-pertussis and 
measles-mumps-rubella. By 1999, the CDC recommended that children were to receive 
twenty-two vaccinations by the time they reached first grade. Despite many warnings, 
including members of their own staff, thimerosal continued to be put into childhood 
vaccines. At two months of age, infants were recommended to receive three 
inoculations that contained a total of 62.5 micrograms of ethylmercury, 99 times greater 
than the EPA's limit for daily exposure to methylmercury, a related neurotoxin. There 
have been several research studies suggesting ethylmercury is actually more toxic to 
developing brains and stays in the brain longer than methylmercury (Clarkson. 2002). 
 On April 22, 1998 the FDA completed its proposed ban on the over-the-counter 
use of thimerosal from topical ointments and skin creams. This decision is based on a 
report from their advisory committee that was submitted in 1980, eighteen years 
previously.  
 In 1999 the U.S. Public Health Services (USPHS) and the American Academy of 
Pediatrics (AAP) issued a joint statement in which they identified thimerosal as a 
widespread organic mercury exposure in infants/small children and recommended that it 
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should be reduced or eliminated from childhood vaccines (Centers for Disease Control 
and Prevention, 1999). 
 A subset beneath the CDC is the “Agency for Toxic Substances and Disease 
Registry” (ATSDR). In their April 1999 release of information, mercury is listed as a toxic 
substance. They state,  
"The nervous system is very sensitive to all forms of mercury. Very young children are 
more sensitive to mercury than adults. Mercury's harmful effects that may be passed 
from the mother to the fetus include brain damage, mental retardation, incoordination, 
blindness, seizures, and inability to speak. Children poisoned by mercury may develop 
problems of their nervous and digestive systems, and kidney damage. Effects on brain 
functioning may result in irritability, shyness, tremors, changes in vision or hearing, and 
memory problems."  (www.atsdr.cdc.gov) 
 
The symptoms listed by the ATSDR as mercury poisoning do correlate with symptoms 
of autism. 
The CDC does not follow their own advice as found in the ATSDR's final 
comment on mercury, "Properly dispose of older medicines that contain mercury. Keep 
all mercury-containing medicines away from children." Ironically, the ATSDR who is 
directly under the supervision of the CDC has stated for years to keep mercury 
containing medicines away from children, yet children are still given vaccines containing 
thimerosal today through the influenza vaccine.  
 By 1999, there was a compilation of research relating to people's different 
sensitivity to mercury, almost reflecting that of an allergic reaction. Most of the research 
reflected the topical use of mercury, however there was substantial research also with 
the inoculations. Stejskal  & Stejskal (1999), Associate Professor of Immunology in the 
Department of Clinical Chemistry at Danderyd Hospital and Karolinska Institute in 
Stockholm, Sweden, has extensively published on adverse effects of metals on the 
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human body. One publication in "Neuroendocrinology Letters" titled, "The role of metals 
in autoimmunity and the link to neuroendocrinology" stated,  
"In contrast to the toxic effects of metals, the concentration of the metal in a sensitized 
individual is of minor importance. Minute concentrations of an allergen can induce 
systemic reactions in sensitized individuals. In such a situation, metal induced 
inflammatory reactions in the brain or elsewhere could be triggered despite low 
concentrations detected in body fluids or locally" (p. 10).  
 
Stejskal has also developed a blood test to diagnose a person's allergy to metal that is 
available in the United States; however, it is not used. This could offer one reason why 
some children appear to be more sensitive to the outcomes of mercury poisonings and 
the possible genetic link with the sensitivity. 
 June 28, 1999, Dr. Barry Rumack, a consultant to the FDA, developed a 
pharmacokinetic model to analyze the amount of mercury to which infants are being 
exposed. He demonstrated most children born in the 1990's received doses of 
ethylmercury through vaccination that exceeded the EPA's limits for exposure to 
methylmercury, which was 0.1 micrograms per kilogram, and the FDA's limits of 0.4 
micrograms per kilogram, during the first six months of their life. The safety limits were 
also in excess of those established by the ATSDR and WHO (Peterson, 1978; 
Congress, 2003).  
 In response to the heated concern over thimerosal the CDC's Advisory 
Committee on Immunization Practices (ACI) met in Atlanta, Georgia. One issue 
presented was the option of stating a preference for the thimerosal-free DTaP, Hib and 
Hepatitis B. The DTaP thimerosal-free vaccine was now in production by SmithKline 
Beecham. The other three manufacturers, Aventis Pasteur, North American Vaccine 
and Wyeth, were still producing vaccines with thimerosal. Manufactures of the Hib and 
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Hepatitis B vaccine had recently converted to thimerosal-free or contained trace 
amounts of thimerosal, however, older versions on these vaccines containing thimerosal 
were still in inventory hence being used around the country. The conclusion was the 
CDC officials, led by Bernier, would not state a preference for thimerosal-free vaccines. 
His reasoning, it could entail financial losses if current vaccine inventory is wasted. It 
could harm one or more manufacturers and may then decrease the number of 
suppliers. He went on to compare it to the transition from oral polio to inactivated polio. 
In the end, the advisory committee voted unanimously not to state a preference for 
thimerosal-free vaccines (Levin, 2004).  
 In the fall of 1999 the CDC obtained data from the Vaccine Safety Database 
(VSD) to begin a study of the possible link between thimerosal and Neurodevelopmental 
Disorders that were documented to be caused by mercury exposure in children. Some 
of these conditions were Autism, Attention Deficit Disorder, Attention Deficit 
Hyperactivity Disorder, Speech Delays, Language Delays, Eating Disorders, Sleep 
Disorders, Emotional Disorders, Behavioral Disorders, Coordination Disorders, Tics, 
and others. Kidney disorders and, as a control, disorders not known to be associated 
with effects from mercury such as Mental Retardation and Cerebral Palsy were also 
added (Vaccine Safety Datalink Project, CDC). The first analysis showed a comparison 
of children who never received thimerosal compared to those who had. The results in 
the Neurodevelopmental Disorders demonstrated a level of causation in Autism, 
Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder, Coordination 
Disorder, Sleep Disorders, Tic Disorders, Speech and Language Disorders, Convulsive 
Epilepsy and Kidney Disorders.  
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In a letter from Congressman David Weldon (R-Fla) to the director of the CDC, 
Dr. Julie L. Gerberding (copy in Appendix B), Weldon discuss Dr. Verstraeten’s study 
“found a significant association between exposure to thimerosal containing vaccines 
(TCVs) and autism and neurological developmental delays (NDDs).” (Weldon, personal 
communication October 31, 2003).   In response to the investigation, on December 17, 
1999 at 4:40 PM, Dr. Thomas Verstraeten sent an e-mail to Robert Davis, CC’d to 
Frank DeStefano titled: "It just won't go away." In the e-mail Dr. Verstraeten discusses 
the different methods he used in the analysis. One method he wrote about was to drop 
the data of children who received the Hepatitis B Immunoglobulin. This vaccine 
contained 37.5 micrograms of mercury from thimerosal and was given at birth. When he 
eliminated those children, about 1/4 of most disorders and 1/3 of the autism cases were 
also eliminated. He concluded, "that except for epilepsy, all the harm is done in the first 
month." He referred to autism, Attention Deficit Disorder, Speech and Language 
Disorders, Sleep Disorders and Coordination Disorders as the "first five."  He ended 
with, "...I haven't yet found an alternative explanation...Please let me know if you can 
think of one." All of the research conducted by Dr. Verstraeten was never released to 
the public, or given to Congress to evaluate during their investigation. Dr. Verstraeten 
was also questioned for falsely stating he “worked” for the CDC when he actually 
obtained his salary from GlaxoSmithKline (GSK). However, almost four years later, in 
the journal Pediatrics, he published the opposite, no correlation to any 
neurodevelopmental problems related to thimerosal exposure to infants (Verstraeten, 
2003; Verstraeten, personal communication, December 17, 1999).  
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During the late 1980's to the early 2000’s infants may have been exposed to a 
total of 237.5 micrograms of mercury during the first 18-24 months of life, if all 
thimerosal containing vaccines were received. 
 By April 2000 the statistics still were showing a correlation between thimerosal 
and autism. Concerned with the outcome, Coleen Boyle from the CDC advised more 
changes to manipulate the date in an e-mail to Frank Destefano entitled "comments of 
analysis." "Since most of the dx's [diagnosis] are generally not picked up until the 2nd or 
3rd year of life had you considered eligibility criteria of at least 18 months or 2 years?? 
What happens if you do this? [Also], early dx of these disorders is strongly associated 
with SES -- can you control for your marker variable of SES (Not sure SES is related to 
thimerosal, but surely compliance with vaccination schedule.)" (Boyle, personal 
communication, April 25, 2000).  
 The Committee on the Toxicological Effects of Methylmercury (2000), Board on 
Environmental Studies and Toxicology, National Research Council published 
Toxicological Effects of Methylmercury in the National Academy of Sciences. In it they 
stated a correlation between the autoimmune disorders and mercury (National 
Research Council [U.S.]. Committee on the Toxicological Effects of Methylmercury, 
2000). James, et al., (2005), FDA scientists, stated in the Journal of Neurotoxicology 
"Thimerosal crosses the blood-brain and placental barriers and results in appreciable 
mercury content in tissues including the brain" (James, et al., 2005 p. 5).  
In April 2000, a document, “Autism: A Unique Type of Mercury Poisoning” was 
authored by Bernard, Enayati, Binstock, Roger, Redwood and McGinnis. They 
demonstrated similarities between the mercury poisoning, Acrodynia, commonly 
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referred to as Pink Disease, and children with autism. They refer back to the studies 
that show Acrodynia can occur from very small exposures. They concluded that 
mercury might be the likely etiology of Autism Spectrum Disorder, deriving from 
thimerosal in vaccines, "due to the extensive parallels between autism and HgP 
[mercury poisoning], the likelihood of a causal relationship is great" (Bernard, 2003 p. 
467).  
 On June 7th and 8th, 2000 a very controversial meeting was held by the CDC at 
the Simpsonwood Retreat Center in Atlanta, Georgia. Those in attendance were the 
CDC Advisory Committee on Immunization Practices, members of the American 
Academy of Pediatrics, The National Immunization Program, the Chief Medical Officer 
for the Vaccine Injury Compensation Program, a representative with the European 
Agency for the Evaluation of Medicinal Products, a representative for the World Health 
Organization (WHO), the FDA, and representatives with HMO organization Northern 
California Kaiser, as well as pharmaceutical company representatives for SmithKline 
Beecham, Merck, North American Vaccine, Aventis Pasteur, and Wyeth. The 
controversy arose over the fact that the meeting, as required by law, was not 
announced publically in the Federal Register. The original transcripts of the meeting 
were stamped on the top of each page, “DO NOT COPY OR RELEASE” and 
“CONFIDENTIAL.” However, today the entire transcript is available through the 
Freedom of Information Act.  
The contents of the meeting were nothing less than frightening in regards to the 
knowledge that was being kept from the public. In response to thimerosal and autism 
Dr. Weil comments, "The number of dose related relationships are linear and 
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statistically significant. You can play with this all you want, they are linear. They are 
statistically significant" (Simpsonwood, p. 207).  
 By July of 2000 the data collected by the Congressional Investigation 
documented an average of 8,000 children daily were being exposed to mercury that 
exceeded all federal guidelines. During the congressional hearing, Dr. Stephanie Cave, 
a physician who specialized in children with symptoms of autism testified before 
Congress. She discussed the tremendous increase in her patients with autistic 
symptoms. She referenced treating over 300 of these children with a waiting list of 150 
more. She closed by stating autism to be a true epidemic and challenged anyone who 
disagreed to sit in her office for a few hours. After listening to the testimonies, 
Congresswoman Helen Chenweth-Hage expressed her frustration to Congress. She 
questioned members of the Federal government agencies who were still denying that all 
types of mercury are toxic and could cause harm. Her testimony included her 
statements,  
"You listened to the testimony just as I did, and you are willing to, with a straight face, 
tell us that you are eventually going to phase this out after we know that a small baby's 
body is slammed with 62 times the amount of mercury that it is supposed to have...It 
doesn't make sense. No wonder people are losing faith in their government. And to 
have one of the witnesses tell us it is because mothers eat too much fish! Come on. We 
expect you to get real. We heard devastating testimony in this hearing today, and we 
heard it last April. And this is the kind of response we get from our government 
agencies? I am sorry. When I was a little girl, my daddy talked to me about something 
about a duck test. I would ask each one of you to read this very excellent work by Sallie 
Bernard and Albert Enayati, who testified here today. My daddy used to say if it walks 
like a duck and talks like a duck and sounds like a duck, for Pete's sake it is a duck. I 
recommend that you read this, side-by-side, page after page of analysis of the 
symptoms of people who are affected with mercury poisoning compared to autism. This 
is the duck test, and you folks are trying to tell us that you can't take this off the market 
when 8,000 children are going to be injected tomorrow; 80 children may be coming 
down, beginning tomorrow, with autism? What if there was an E. coli scare? What if 
there was a problem with an automobile? Mr. Egan, [FDA] I will address this to you. You 
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know, it was shown in the last panel that autistic symptoms emerge after vaccination. It 
was shown that vaccines contain toxic doses of mercury. It was shown that in autism 
and mercury poisoning, the physiological comparison is striking. There is altered 
neurotransmitter activity, abnormal brain neuronal organization, immune system 
disturbance, EEG abnormalities. It goes on and on and on, the comparisons. That is 
why I say, I back up what the Chairman and the ranking member are all asking you, that 
we cannot wait until 2001 to have this pulled off. You know, if a jury were to look at this, 
the circumstantial evidence would be overwhelming. Let's do something before we see 
it in the courts.”                                                                   (Congressional Hearing 2000) 
 
Dr. Bernard Rimland, one of the most recognized researchers in the field of 
autism, began his research regarding connections between autism and vaccines. He 
had a data base, through the Autism Research Institute, where he collected data from 
over 30,000 cases of autism worldwide. His findings led him to conclude that before the 
early 1980’s most parents of children with autism reported the conditions at birth or in 
the first year of life. In contrast, after the mid-1980’s the parent’s reports began to 
change to after the first eighteen months of life (Rimland, 2000).  
Pollard, Pearson, Hultman, Deane, Lindh, & Kono (2001) conducted a study that 
showed that mice genetically susceptible to autoimmune disease developed a mercury-
induced autoimmune disease after treatment with inorganic mercury. The researchers 
conclude with their findings "suggests that environmentally relevant tissue levels of 
mercury could be associated with exacerbations of autoimmunity in genetically 
susceptible hosts" (p. 30).   
 Fournie et al., (2001) published a study done in France looking at the effects of 
thimerosal on the autoimmune system.  Their findings suggested that compounds such 
as thimerosal can trigger the development of autoimmunity through a bystander effect.  
They went on to say that understanding this effect can lead to better knowledge in 
screening individuals who could be at risk.   
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 Sanfeliu, Sebastia, and Ki (2001) published a study in "Neurotoxicology" called, 
"Methylmercury Neurotoxicity in Cultures of Human Neurons, Astrocytes, 
Neuroblastoma Cells." The study implicates reactive oxygen species (ROS) and 
depletion of intracellular glutathione as major contributors to mercury-induced 
cytotoxicity, with neuroblastoma cells being the most sensitive to the mercury. 
Glutathione deficits are documented as a common trait in children with autism (James, 
Rose, Melnyk, Jerigan, Blossom, Pavliv, & Gaylor, 2009).  
On April 25 and 26, 2001 there was another Congressional Hearing entitled, 
"Autism: Why the increase rates?" Dr. Boyd Haley, Chairman of the Chemistry 
Department at the University of Kentucky, testified after eleven years of studying the 
toxicity of mercury. Haley begins his testimony stating he was requested to perform an 
evaluation on the toxicity of vaccines containing thimerosal versus thimerosal free. 
Haley went on to compare his results with the toxicity reports of 1986, stating his results 
were very dramatic in relation to the toxicity of thimerosal. Haley responded to 
questioning by Burton,  
“I am probably one of the few people here who does not treat patients. I am a research 
scientist and I work in a lab. I was asked some time ago to look and go to the bottom 
line. Are the vaccine mixtures that we are placing in the children toxic? If they are going 
to have an effect on autism or any disease or any neurological disorder, there is a good 
possibility, if it comes from the chemical level, that vaccines have to show some toxicity 
at the molecular level. We did test vaccines, and I will make this very short because I 
know we are in a hurry. We compared the vaccines with and without thimerosal from the 
same source, the same type of vaccine, and those with thimerosal present were 
remarkably much more toxic--over 10-fold to 100-fold more toxic than those without 
thimerosal. There was one outstanding exception, and that was the MMR vaccine. The 
MMR vaccine was as toxic as the vaccines with thimerosal, but there is no thimerosal in 
the MMR. We measured I would point out also that the toxicity is thimerosal in a vaccine 
mixture. In our studies, we looked at combined toxicities because we are not rats living 
in a pristine cage. Aluminum is a neurotoxin, formaldehyde is neurotoxic, and you 
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throw that in with thimerosal, which breaks down to ethyl mercury, a well-known toxin.” 
(p. 63)  
 
When drilled about his study of non-thimerosal vaccines Haley reported,  
 
Dr. Haley. We looked at the level of mercury. It fit what you would expect. There are low 
levels of mercury in the non- thimerosal-containing vaccines. There is some in all of 
them. The ones that had thimerosal added were quite high. The MMR came across as if 
it had no thimerosal added. There was a small amount in there. I think it would be 
similar to those that had no thimerosal added. There was mercury in there, but not very 
much. (p. 79-80) 
Mr. Burton. There was mercury in the MMR vaccine? 
Dr. Haley. Yes, but a very small amount. 
Mr. Burton. But there was mercury in the vaccine? 
Dr. Haley. Yes, but the toxicity---- 
Mr. Burton. Merck, when we called awhile ago, said that there was no mercury in the 
MMR vaccine. You are saying that there was a very small amount. 
Dr. Haley. Yes, we found it. I would want to do 20 of them before I came up with an 
average, but we did find a small amount of mercury. It was very tiny, though. The MMR 
vaccine, unlike those vaccines without thimerosal, was very toxic. It was as toxic as if it 
had thimerosal in it. 
Mr. Burton. So would you say it was 10 times more toxic than a vaccine without 
thimerosal? 
Dr. Haley. I would say so, yes. (p. 80) 
 
Haley went on to discuss the inability of infants to effectively remove mercury and 
aluminum from their systems. Haley discussed the fact that the best known way of 
removal of mercury is through their bile, and consequently infants do not make bile in 
their early months of life, and the removal of aluminum in the renal system, however, 
infants do not have a fully developed renal system, hence, they would therefore be 
unable to remove mercury and aluminum through the bilary transport and renal system. 
(Congress of the U.S. 2001).   
Lucier (2001), a toxicologist and former Director of the Environmental Toxicology 
Program at the National Institute for Environmental Health Sciences presented a slide of 
the "Comparative Toxicity of Ethyl and Methyl Mercury" to the Institute of Medicine 
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Immunization Safety Review Committee July 2001.  The presentation concluded 
thimerosal is a potentially toxic substance. On slide number 14, he listed the "Clinical 
Manifestations of Ethylmercury Poisoning Episodes" as: speech disorders, vision 
disorders, tremor, ataxia, spasticity, delirium, and death.  
By mid-2001, vaccine manufactures independent from the CDC had claimed to 
have completed their transition to "thimerosal-free" or "trace amounts of thimerosal" Hib, 
DTaP, and Hepatitis B vaccine.   However, due to the stockpiles of vaccines still 
available in the physician's office the transition did not occur until late 2001 to early 
2003. However, The Health Advocacy in Public Interest (HAPI) conducted a study of 
"mercury free" vaccines. Four vials were sent to Doctor's Data, an independent lab that 
specializes in heavy metal testing. The lab found all four vials contained mercury. 
According to Haley, the mercury binds to the antigenic protein in the vaccine making it 
impossible to completely filter out the mercury. (The manufactures still use thimerosal in 
the production of vaccines because thimerosal is still a component in vaccines sent to 
third world countries.) In contrast, the CDC began to recommend pregnant women, 
infants and children receive a yearly flu vaccine, which contains thimerosal. 
July of 2001 again proved to be a controversial time in the vaccine industry. 
Verstraeten, the lead researcher in the CDC studies, was asked to testify at a meeting 
held by the Institute of Medicine about the safety of thimerosal and its link to autism. He 
began his testimony with the announcement that just hours before the meeting he was 
hired by GlaxoSmithKline, one of the vaccine manufactures who produced thimerosal 
vaccines and who was named in a lawsuit filed by parents of autistic children. Even 
after his announcement, Verstraeten continued to work on the CDC study designed to 
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determine if there was a connection between neurodevelopmental disorders and autism 
despite an apparent conflict of interest as being an employee of the vaccine 
manufacturer.   
October 2001, Merck Pharmaceuticals continued to send out the remaining 
thimerosal Hepatitis B vaccine to pediatricians that were manufactured in 1999. Due to 
the fact that they had made a statement that all Hepatitis B vaccines being 
manufactured were now mercury free versions most parents and physicians were 
unaware that they were still receiving vaccines with mercury. The vaccines were 
marked to expire during the year 2003. 
In January 2002, for the first time ever, the CDC's Advisory Committee on 
Immunization Practices recommended that pregnant women in their second or third 
trimester and infants between 6 months and 24 months to get a flu vaccine. Flu shots 
still contain a full dose of thimerosal, 25 micrograms, with only one manufacturer, 
Evans, producing a flu vaccine with reduced Thimerosal.  
 February 2002 Dr. Thomas Clarkson, with the Department of Environmental 
Medicine at the University of Rochester School of Medicine in New York published his 
findings on mercury. He referenced the amount of mercury already found in adults and 
children from eating fish and how thimerosal in vaccines compiles with it. Clarkson 
concluded with, "In attempts to estimate health risks from thimerosal in vaccines, a key 
gap in our knowledge on the human toxicology of mercury has become apparent. Little 
is known about the tissue distribution and toxicity of mercury in human infants, or in 
animals for that matter" (Clarkson, 2002, p. 17). 
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 Westphal (2002), Department of Occupational Health in Gottingen, Germany 
published his findings on thimerosal.  The purpose of the study was to evaluate the 
relationship between thimerosal and the levels of glutathione S-transferase (GST) which 
is the body's defenses against thimerosal. They concluded their research with, "In 
conclusion, thimerosal induced strong effects in the cytochalasin B block in vitro 
micronucleus test in human lymphocytes. Inter-individual differences in the response 
were not linked to different GST genotypes. Since thimerosal was repeatedly shown to 
be genotoxic in vitro and in vivo, there is reason for concern about its widespread use" 
(p. 54). 
 On December 10, 2002 there was another committee hearing in Washington, 
before the House of Representatives. One of those who testified was Dr. David Baskin. 
He introduced himself by stating,  
"I’m a professor of neurosurgery and anesthesiology at Baylor College of Medicine. I’m 
a neurosurgeon. I do complex spine and brain surgery, about 350 cases a year. I have 
also been involved in research, looking at ways to protect the nervous system from 
damage and to reverse damage, for over 20 years, and have over $1 million in Federal 
funding, both from NIH and BIA, as well as State funding and private funding from 
foundations, to look at a variety of issues in terms of brain damage" (Baskin’s testimony 
if found in Vaccines and the autism epidemic: Reviewing the federal government’s track 
record and charting a course for the future 2002, p. 30). 
 
When questioned about thimerosal his response was, "We are talking about a known 
poison, neurotoxin, that’s been added to these vaccines with the initial idea that it would 
function as a preservative." He goes on to say, "Thimerosal was placed in vaccines in 
the late 1930’s; and guess what: Three years later Kanner first described the syndrome 
of autism—never ever been described before in the medical literature. The neurotoxicity 
of mercury has been very well established in terms of brain injuries since the 1960’s, as 
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you’ll see." He goes on to explain the Iraq case when ethylmercury was used as a 
fungicide on grain and the knowledge that was gained about the neurological damage. 
When comparing what we have learned from past research and our current findings of 
autism he testifies,  
"The brain damage in these cases was studied, and it’s interesting that the type of brain 
damage seen was the loss of the Purkinje cells, which are cells in the cerebellum, and 
the loss of the cortical column, which is the part of our brain that is involved in complex 
thought. And guess what: At the recent meeting for autism research at the Society for 
Neuroscience, this exact same histopathology has been described in autism” (p. 34).  
 
He goes on to name numerous studies that show evidence for the correlation between 
mercury poisoning and autism. He was asked in summary if he personally believed from 
his studies that mercury is a contributing factor to the cases of autism we have in this 
country. He answered with a simple, "Yes."  He went on to discuss some of his 
research,  
"We have the opportunity to actually grow human frontal cortex cells in cell culture. So 
these are cells from the front part of the brain that grows in culture. We incubate these 
cells with thimerosal at various doses, and we use a number of very sophisticated 
techniques to detect cell death and cell damage....These are the cells committing the 
suicide program and breaking themselves into tiny little pieces with a very low dose of 
mercury" (p. 46).  
 
He continues,  
 
"Here is a slide where you see a lot of blue cells. This is a blue dye that normal cells 
don't take up. In order for something to turn blue, the cell has to have holes punched in 
their membranes. And guess what: At an extraordinarily low dose of thimerosal, most of 
the cells are blue. It means that this stuff grabs hold of the membrane and punches 
holes into it, so that the dye can penetrate, not only into the cytoplasm but into the very 
center of the cell, the nucleus, where all the DNA exists. We found this to be dose-and 
time-dependent. We found that 101 nanograms per gram is the lowest dose we’ve 
studied, and it’s toxic. And we didn’t even expect this to be toxic, yet if you consider a 
five-times preferential uptake and you use FDA numbers, infants receive 380.5 
nanograms, three times the dose that we found to be toxic to brain cells" (p. 47).  
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Baskin at Baylor College of Medicine demonstrated, “that thimerosal in 
micromolar concentrations rapidly induces membrane and DNA damage and initiate 
caspase-3-dependent apoptosis in human neurons and fibroblasts.” The researcher 
summaries the research with the need for more research in the area of toxicity of 
thimerosal since mercury can be retained in body organs for months to years (Baskin, 
Ngo, and Didenko, 2003, p 361).  
Qvarnstrom, Lambertsson, Havarinasab, Hultman, and Frech (2003) published a 
study done in Sweden that analyzed the distribution of thimerosal into the tissue of 
mice. The researchers used Inductively Coupled Plasma Mass Spectrometry (ICPMS) 
which uses radioactive isotope labeling of mercury to determine the distribution of 
mercury species transformed from standard ethylmercury in the thimerosal.  They 
concluded that thimerosal is rapidly taken up in organs, it is considered to be converted 
to inorganic mercury more rapidly than methylmercury. They go on to clarify their 
findings of the ethylmercury carbon bond being less stable than that of methylmercury. 
These findings could offer evidence as to the enhanced toxicity of thimerosal as 
opposed to the methylmercury found in fish. 
It was not until 2003 that the makers of the Rho-GAM, now given to Rh-negative 
women in their twenty-eighth month of pregnancy and immediately after birth, removed 
the thimerosal. However, that same year the CDC and its Advisory Committee for 
vaccines still refused to state a preference for thimerosal-free vaccines, four years after 
the joint statement, the U.S. Public Health Services (USPHS) and the American 
Academy of Pediatrics (AAP) made the recommendation for the removal of thimerosal. 
According to the FDA, children were still recommended to get shots containing 
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thimerosal in vaccines: DTaP, Hib and Hepatitis B until the expiration dates expired in 
January 2003.  
  In June 2004, a study lead by Mady Hornig at Columbia University explored 
more into the effects of thimerosal on the autoimmune system and autistic like 
symptoms. In their report, the findings are again demonstrating the potential harm 
caused by thimerosal. There studies were done by giving mice thimerosal.  They 
reported that exposure to thimerosal can increase the risk of autism-like damage in 
autoimmune strains of mice, including increased brain size. Other symptoms found 
were growth delay, reduced locomotion, anti-social behaviors, a decreased number of 
purkinje cells, densely packed hyperchromic hippocampal neurons with altered 
glutamate receptors and transporters, and significant abnormalities in brain architecture 
affecting areas subserving emotion and cognition  (Hornig, Chian, & Lipkin, 2004). 
 On July 27, 2004, a group called Health Advocacy in the Public Interest (HAPI) 
had a meeting between their executive director, Dawn Winkler, and the FDA. The 
concern presented was the misrepresentation of ingredients in vaccines as licensed by 
the FDA through mislabeling, specifically labeling that stated mercury-free. The group 
had previously had four vaccines tested at a private laboratory, Doctor's Data, an 
independent lab which specializes in heavy metal testing. What they discovered is 
thimerosal is still being used in the vaccines, although they are not promoting it as a 
preservative. The vaccine manufactures claim was they were "filtering out" the 
thimerosal. Dr. Boyd Haley confirmed that mercury binds to the antigenic protein in 
vaccines; therefore, mercury cannot be completely filtered out. Two of the vials 
containing mercury were stated, "mercury free." Haley took a position to state that if 
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mercury can be detected in any vaccine using standard instrumentation, the content 
should be disclosed in the product insert and should not be labeled "mercury free." 
Another concern was all four contained aluminum, with one of the vials containing nine 
times more than the other three (Winkler, 2004). Aluminum mixed with mercury, as 
shown in the 1973 reports, greatly enhanced the toxicity (Burton 2003; Fiasco 2002). 
 September 2004, the United Kingdom banned all thimerosal-containing vaccines 
due to their concern of neurotoxicity, and more specifically the links between metal and 
autism. At this time many states have independently banned thimerosal containing 
vaccines; however, the federal government has not made this stand and further, the 
Homeland Security Bill allows the federal government to issue “forced vaccines,” 
including those tainted with thimerosal.  
 On February 8, 2005 an article came out in the Los Angeles Times, by Myron 
Levin, disclosing a memo a whistle blower released from Merck regarding their 
knowledge about the amount of mercury given on the vaccine schedule. The memo was 
from Dr. Maurice Hillman to Gordon Douglas in March 1991. Hillman said in the memo 
that "6-month-old children who received their shots on schedule would get a mercury 
dose up to 87 times higher than guidelines for the maximum daily consumption of 
mercury from fish.  “When viewed in this way, the mercury load appears rather large,” 
said the memo from Dr. Maurice R. Hilleman, an internationally renowned vaccinologist. 
It was written to the president of Merck’s vaccine division (Levin, 2005). This was eight 
years before the health officials requested the removal of thimerosal from vaccines. 
Merck blamed the printing company for failure to copy the information in the memo to 
inform all of their staff.  
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 March 6, 2008, a decision about an influential suit against the federal 
government was ruled on. Hannah Poling became the first case in which the federal 
authorities have conceded a connection between her autistic symptoms and the 
vaccines she received. A panel of medical evaluators at the Department of Health and 
Human Services concluded that Hannah had been injured by vaccines, thus came the 
recommendation that her family be compensated for the injuries. The panel said that 
Poling had an underlying cellular disorder (a mitochondrial dysfunction) that was 
aggravated by the vaccines, causing brain damage with features of Autism Spectrum 
Disorder (ASD). Because of a series of ear infections, Hannah had fallen behind in the 
vaccine schedule, so in a single day she was given five inoculations covering nine 
diseases: measles, mumps, rubella, polio, varicella, diphtheria, pertussis, tetanus, and 
Haemophilus influenzae. Not only was that a large dose of thimerosal, but a concerning 
level of viruses on one given day. The biggest question throughout the hearing was if 
the mitochondrial dysfunction was a result from the vaccines or the cause of the injury, 
that question was left unanswered. 
 Thimerosal, or mercury, in vaccines has been a controversial debate since the 
mid-1980's as to its effects on autism. There have been numerous studies comparing 
the behaviors of children with autism to those of mercury poisoning. Some have 
questioned why only some are affected and others are not. The above researchers 
answer that question with studies on the genetic make-up of those who are predisposed 
to a sensitivity to mercury versus those who are not; just as some can smoke and not 
get lung cancer, or someone directly exposed to a virus does not get sick while the 
person on the other side of the room is more susceptible to the virus and becomes ill.  
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Ever since 2005, most vaccines have removed thimerosal, except some DTaP and 
Influenza.  However, the controversy over thimerosal and autism is still very much alive, 
some would go as far as to say due to the extensive parallels between autism and 
mercury poisoning the likelihood of a causal relationship is plausible.  
Vaccines and Viral Overload 
The second concern with vaccines and the relationship to autism lies in the 
relationship between viruses, autoimmune dysfunction, and the impact on the 
gastrointestinal (GI) system. Dr. Asperger also identified a link between celiac disease 
and their behavior (Asperger, 1961). 
In the 1980’s autism numbers began increasing at an alarming rate, at the same 
time the MMR vaccines was introduced.  Wakefield, a leader in the philosophy of a 
connection between autism and the MMR vaccine, along with a team of researchers 
explored the connection between the MMR and autism. Wakefield, et al (1998) research 
documented, "evidence of anemia and IgA deficiency in some children, would support 
the hypothesis that the consequences of an inflamed or dysfunctional intestine may play 
a part in behavioral changes in some children" (Wakefield, 1998, p. 639). As a doctor of 
gastrointestinal medicine, he felt there was a correlation between the GI symptoms and 
autistic children. Several doctors in practice with him did intestinal biopsy samples on 
160 children with GI issues, 90 autistic and 70 control. The results were the discovery of 
the measles virus in 75 of the 90 children with autism, but only 5 of the 70 control. This 
finding led him to the philosophy if he would treat the GI issues it may relieve the autistic 
behavior. Since that time Wakefield has published over 135 peer reviewed articles.  
Wakefield was not the only one looking at the GI connection with autism. Dr. Bernard 
  56 
 
 
 
Rimland, after over 40 years of studying autism at the time also agreed with Dr. 
Wakefield's findings (Rimland, 2000). He also referred to Andrew Wakefield’s work 
linking the MMR vaccine to autism, as a link to the large increase with “late-onset of 
autism” that arose during the 1980’s when the MMR was first administered. Dr. Brent 
Taylor also did a study on the connection between the MMR and autism. Taylor’s 
reported no connection. The article was also published in The Lancet, refuting 
Wakefield’s study. As a researcher, Rimland asked for a copy of the data from Taylor’s 
study published in The Lancet in order to reanalyze, a common professional courtesy. 
Taylor refused, as did the editor of The Lancet. Dr. Rimland, amongst many, has asked 
The Lancet to retract Taylor’s comments if the data cannot be made available for 
reanalysis. The Lancet has been inconsistent with the issue. Even with the debate, the 
link to autism and the GI issues has grown, and more doctors are treating the GI issues 
in hopes to change the negative behavior of children with autism.  
 Wakefield is not the only one researching the GI connection with autism. Robert 
Bryd, principal investigator, in the California study, also in his summary of his research 
project stated a common trait of the autistic children born between 1983-1985 was 
gastrointestinal symptoms, including constipation and vomiting (MIND, 2003). In June 
2006, Stephen J. Walker, Ph.D., an assistant professor of physiology and pharmacology 
at Wake Forest University Baptist Medical Center issued an abstract to be presented at 
the International Meeting for Autism Research. His research evidenced a high 
percentage of autistic children, tested by his colleagues and himself, as having chronic 
bowel disease. Walker explains that exploring the causes of chronic bowel disease in 
autistic children is the major impetus for his research. He expressed that the bowel 
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condition has a direct influence on cognitive and behavior issues that are associated 
with autism. He stated,  
“These kids experience it hour after hour every single day of their lives. Many of them 
are non-verbal so they can’t tell anybody what the problem is, and the behavior that 
they exhibit as a result of a severe stomach ache was once attributed to just being 
autistic and having weird behaviors, for example, leaning over the sharp edge of a 
coffee table for hours at a time. That seems weird, but what they’re doing is relieving 
pressure on their lower abdomen” (Press release from Wake Forest Baptist Medical 
Center, Walker 2008).  
 
Posturing is a common trait of autistics that is researched in conjunction with GI issues. 
He goes on to state, “There’s case after case where kids improved cognitively, 
behaviorally and biomedically when you treat the bowel disease. There is a great 
improvement from better nutrition alone. You see improvements in their overall 
condition” (Walker, International Meeting for Autism Research Montreal, Canada 2006). 
 Over the past few years, there has been extensive publicity in the area of autism 
and GI issues. The focus has been to treat these conditions with the gluten free/casein 
free diets (GF/CF). Parents who have done the diet have made statements including 
their child has recovered, speech has begun, no longer fussy, and more attentive. Much 
of the publicity stemmed around the actress Jenny McCarthy when she announced her 
autistic son had recovered from autism by the diet. Many refute these statements saying 
these children are not actually autistic to begin with, but it is hard to convince the 
parents of these previously diagnosed children they have not recovered, or shown great 
improvements (Elder, Shankar, Shuster, Theriaque, Burns, Sherrill, 2006).  
 The link between gastrointestinal problems and autism appears to show a 
connection, especially in the 1980's. Some researchers link it to the MMR vaccine, but 
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the reason for the link appears to be coupled with the autoimmune dysfunction of those 
children and their sensitivity to the overload of viruses in their system.  
Vaccines and Autoimmune 
Singh (2002) has published extensively on the issue of autism and autoimmune 
disease. Along with Singh’s research there are numerous other studies regarding the 
deficits of autoimmune system, all using the basic science of autoimmune disease 
generally suspected of being triggered by viruses, hence the correlation with the MMR. 
In one study, Singh, Lin, Newell, and Nelson (2002) used serum samples of 125 
autistics and 92 control. The antibodies were analyzed by Enzyme-linked Immuno 
Sorbent Assay (ELISA), a technique used to detect the presence of an antibody or 
antigen. The results of the study showed the autistics had significant increase in MMR 
antibodies, but not in the control group. “Moreover, the elevated level of measles 
antibodies was strongly associated with brain autoantibodies, which led us to postulate 
a pathogenetic association of the measles virus to autoimmunity in autism” (p. 360).  
Singh, et al., (2002) research, along with many others gave evidence that autistic 
children have numerous immune abnormalities: serum IgG3 increase, serum IgA 
decrease, (Gupta, Aggarwal, & Heads, 1996; Plioplys, Greaves, Kazemi, & Silverman, 
1994)  reduced number and function of lymphocytes, especially T helper cells and 
natural killer cells, (Warren, Foster, & Margaretten, 1987; Stubbs & Crawford, 1977) and 
increase plasma levels of autoimmunity-specific cytokines. Singh’s (1996) research also 
had concluded, "Therefore, the increase of IL-l 2 and IFN-7 may suggest a defect of 
immunoregulatory T cells in autism (p.145). Singh’s research referred often to the 
autoimmune system having a significant link to autism.  
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 Singh and Jensen (2003) also studied the correlation with measles and autism in 
the published study, "Elevated Levels of Measles Antibodies in Children with Autism". A 
finding of the study demonstrated the correlation to the autoimmunity may play a causal 
role in autism, as related to the central nervous system, especially to the Myelin Basic 
Protein (MBP).  The findings may be attributed to the correlation that the autistic 
children showed a serological correlation between MMR and brain autoimmunity, i.e., 
over 90% of MMR antibody-positive autistic sera also had autoantibodies to brain MBP. 
This is quite an intriguing observation in favor of a connection between atypical measles 
infection and autism; an atypical measles infection in the absence of a rash and unusual 
neurological symptoms was recently described to suggest the existence of a variant 
measles virus in children and adults. In light of the findings, it may suggest that 
considerable proportion of autistic cases may result from an atypical measles infection 
that does not produce a rash but causes neurological symptoms in some children. The 
source of this virus could be a variant measles virus or it could be the MMR vaccine.  
 On common trait in autism that cannot be disputed is the deficit in the 
autoimmune system. Whether the vaccines, especially the MMR, caused the deficit or 
the deficit was always there genetically is yet to be answered. 
Vaccines and Demyelination 
 The last area of concern in regards to vaccines and autism is the concept of 
overtaxing the body with live viruses that contain viral contaminants that result in 
demyelination. There are several aspects of viral overload. One facet simply being too 
many vaccines given at one given time, causing an overload of viruses in the child that 
their body is unable to handle, often leading to autoimmune issues. (Kawashima, H. 
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Mori, Kashiwagi, Y., Hoshika, and Wakefield, 2000) The other facet is viral 
contamination, the fact that no vaccine is clean of other viruses that are obtained during 
the culturing and DNA acquired from the aborted fetal tissues used in many vaccines, 
hence the overload (Manufacture inserts from: Sanofi, Merck, and GlaxoSmithKline). 
 When a child's body is exposed to excess viral loads the body's response can be 
an inflammatory process in which the vessels become inflamed.  When the vessels 
inflame, one of the responses of the body is hypercoagulabilty, in simple terms the 
tendency to form blood clots, also referred to as excessive thrombus formation. Clotting 
is the body's natural response to injury. This begins when the blood vessel is injured, it 
begins to leak blood, the body stops the leak through hemostasis, where the injured 
blood vessel constricts to reduce blood flow, and platelets adhere to the site of injury 
and clump together to form a platelet plug. This process begins the coagulation 
cascade. During the cascade process the body goes through a sequence of events 
beginning with bringing proteins to the site that create a net of fibrin threads that are 
woven through the platelet plug to strengthen the blood clot. The clot acts as a barrier to 
stop continuation of blood loss. However, in the brain this process also reduces the 
cerebral blood flow, not allowing the blood to adequately flow to the cells on the other 
side of the coagulation to bring the necessary oxygen and nutrients. Hence, the 
ischemia leads to hypoxia which leads to continuation of the inflammation. This 
environment traps the toxins, increases free radicals and thus may affects the 
myelination process. These findings regarding the biological effects upon nerves may 
attribute to the behavior and learning deficits of children with autism. 
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 The main purpose of the sheath, or myelin layer, is to increase the speed at 
which impulses move along the myelinated fiber. Nerves can only conduct the energy 
correctly if covered by myelin. When there are unmyelinated fibers the flow of electrical 
current can become interrupted. The myelination helps avoid electrical current from 
leaving the axon; although the axon itself is not damaged it will cease to function if the 
myelin is not properly intact.  When the myelination is not working correctly, a 
demyelinating disease, a disease of the nervous system, is evidenced by the myelin 
sheaths of neurons being damaged. This impairs the message being sent, affecting 
sensation, movement, cognition and other functions that rely on the nerves. There are 
very few pathways of myelin insulation at birth. The myelination continues to form in the 
human brain until about twenty years of age. Typically at the age of ten there are still 
areas of the cortex not yet myelinated. Between ten and twenty years of age the 
myelination of the frontal lobes begin to develop. (Edwards, Meade, Decker, Reed, 
Rennels, Steinhoff, 1995) The demyelination can be caused by an autoimmune 
reaction, or heavy metals, such as mercury (Bigazzi, 1994; Descotes, 1986). The 
myelinated axons are white in appearance, hence the term "white matter" of the brain. 
These connection cables are in the white matter of the brain. There have been 
numerous studies on the white matter differences in autistics. (Waiter, Williams, Murray, 
Gilchrist, Perrett, and Whiten 2005).  
This process is very similar to the "leaky gut" syndrome that is spoken of in 
children with autism, except the inflammation process begins with the viruses in the gut 
and the leaking is reflective with the child having food allergies. (Leaky gut syndrome 
refers to a defect in the intestinal wall, the mucous layer, causing it to become porous. 
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This allows toxic substances, i.e., undigested proteins and fats, parasites, viruses and 
bacteria to enter the bloodstream. When these toxic substances enter the bloodstream 
the immune system reacts by forming antibodies. This becomes the groundwork of food 
allergies and auto-immune conditions.) 
 Another consequence of the virus overload is evidenced when the virus makes 
its way through the blood brain barrier. This can cause the meninges to inflame causing 
meningitis or even encephalitis. Often these symptoms, excessive crying, poor sleeping, 
grabbing head, ataxia, and high fever are not recognized by the medical community as 
an emergency situation. According to the medical community documentation on 
meningitis, viral meningitis is often misdiagnosed as the flu because of its similar 
symptoms. The Emergency Room rarely performs a lumbar puncture to check the white 
cell count in their spinal fluid, which would verify meningitis or encephalitis. Due to flu-
like symptoms the parents are advised to wait it out.  The symptoms may go away in a 
few days, however, the outcome of the encephalitis or meningitis may manifest itself as 
brain damage with traits seen in regressive autism (Gupta, Rapin, Houroupian, Roy, 
Llena, and Tandon, 1984).   
 In order to confirm the correlation between vaccines and autism, a comparison 
study within families would be ideal.  Byrd (2002) attempted to do this during the 
California study. When he interviewed parents to what they felt caused the autism, an 
alarming number blamed the vaccines. He then attempted to do a comparison study 
with younger siblings; however, because such a large number of those parents did not 
vaccinate the younger child, the study, according to Byrd, was not feasible. The next 
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best thing would be to look at populations of people who vaccinate versus those who do 
not, Olmsted and Blaxill (2010) attempted to accomplish this task.  
 In order to look for a comparison of vaccinated children to unvaccinated children 
Olmsted did what he claims is the research the vaccine industry and the media refused 
to do, look for groups of unvaccinated population. The Amish children in rural Lancaster 
became one area of exploration for him. In his discoveries, there were virtually no 
children with autism amongst the thousands of unvaccinated children of the Amish. "I 
have not seen autism with the Amish," said Dr. Frank Noonan, a family practitioner in 
Lancaster County, Pennsylvania, who has treated thousands of Amish for a quarter-
century.  "You'll find all the other stuff, but we don't find the autism. We're right in the 
heart of Amish country and seeing none, and that's just the way it is" (Olmsted and 
Blaxill, p. 156). In dispute to these findings, CDC Director Dr. Julie Gerberding states 
"(the Amish) have genetic connectivity that would make them different from populations 
that are in other sectors of the United States" (Park, 2008). Gerberding presents the 
different genetic connectivity as a fact, although this claim has never been tested. 
Outside of the Amish, in metropolitan Chicago is a fairly large medical practice that has 
served between 30,000 and 35,000 children, Homefirst Health Services. While very 
different from the Amish, what they do have in common with them is the absence of 
vaccinations. Dr. Mayer Eisenstein, the medical director at Homefirst Health Services, 
who also has a Bachelor's Degree in Statistics, a Master's Degree in Public Health and 
a Law Degree, along with his Medical Doctor's Degree, states, "I don't think we have a 
single case of autism in children delivered by us who never received vaccines," His 
practice was founded in 1973. According to Dr. Paul Schattauer, who has been a doctor 
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in their practice for over 20 years, says they treat at least 100 children a week. Dr. 
Schattauer confirms Dr. Eisenstein's observations stating, "All I know is in my practice I 
don't see autism. There is no striking 1-in-166," he said (Homefirst Health Services, 
2010). 
 The correlation between vaccines and autism does present with some strong 
evidence. However, the research that showed improvements in autistic symptoms such 
as behavior, speech and socialization when the children were treated for the reaction 
that may have occurred from the vaccines.   
Etiology: Genetics 
 Pure genetics is another theory as to the etiology of autism, outside of the theory 
of genetic susceptibility. Some claim children with autism would be autistic, no matter 
what, due to genetics.  However, it is statistically impossible to have a genetic epidemic 
in such a short period of time, according to the epidemiologists involved in the Byrd 
(2002) California study. Hence, why much of the research involving genetics and autism 
involves looking at how genetics has a role in susceptibility to toxins and the 
autoimmune dysfunction, again the link back to vaccines (Haley, 2005). Haley (2007), of 
the University of Kentucky, has spent many years studying the effect of mercury on the 
body. He has researched one possible genetic risk factor in autistics. There is a protein 
in the brain called APO-E. Haley refers to this protein as the housekeeping protein that 
removes dangerous waste out of the brain. Some individuals are born with a variety of 
this protein that can effectively remove mercury, APO-E, some people have a variety of 
this protein, APO-E4, that cannot carry out the mercury. Interestingly, when these 
proteins have been analyzed in autistic children a huge number of them had APO-E4. 
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This would reflect in an inability to detoxify the mercury from the vaccines thus being a 
key element in the genetic element of autism. 
 As evidenced by the previous information, when looking at the possible etiologies 
of autism, misdiagnosis, vaccines, or genetics, it appears that some ideas have very 
little validity, while others could clearly be explained more with further research. 
However, one fact is clear; vaccines show a plausible link to autism. One researcher, 
Dr. Bernard Rimland, spent over 50 years researching in the field of autism, leaving the 
field with a tremendous amount of knowledge from his studies.    
Bernard Rimland  
Bernard Rimland, PhD, was one of the first to question autism as an 
emotional/physiological disorder, disputing the “refrigerator mother” theory. After his son 
was born in 1956, he soon found himself in the world of autism. On an interesting note, 
although he had a degree in psychology and a doctorate degree in Experimental 
Psychology his wife was the one to diagnose their son with autism by referencing 
Rimland’s college textbooks. Autism at the time was almost unheard of. In 1964, after 
years of intense research on the subject of autism, Bernard Rimland published his book 
Infantile Autism: the syndrome and its implications for a neural theory of behavior. In his 
book, Rimland, insisted, “Autism is a biological disorder which can be treated with 
biomedical and behavioral therapies” (p. 29) In 1965, he founded the Autism Society of 
America and in 1967 the Autism Research Institute. He is probably best known for his 
intense push for Applied Behavioral Analysis (ABA) in the United States, a therapy 
pioneered by the Norwegian psychologist Ivar Lovaas from the University of California, 
Los Angeles.  Although Rimland fully believed in the practice of traditional educational 
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interventions such as ABA, he did not believe in the traditional theories of the etiology of 
autism. He never left his theory of autism being a result of environmental factors that 
must be addressed and researched.   
 Not dismissing the genetic elements of autism, Rimland was convinced that 
“genetic susceptibility was triggered by external insults.” He cited three main areas, 
environmental pollutants, including food dyes and fertilizers, antibiotics which destroy as 
much as 85% of the good bacteria in the gut (gut flora) causing an increase in Candida 
and GI disorders, MMR and its link to GI disorders, and lastly, he was convinced that 
thimerosal was a vital link to autism (Rimland, 2006).  
 Lastly, after devoting his life to intense research, Rimland was insistent that 
autism was on the increase. He would not accept the theory that doctors and educators 
are just becoming more aware, therefore increasing the diagnosing of autism. In April of 
2000 Rimland testified before the House Committee on Government Reform. He stated, 
“That is nonsense. Any pediatrician, teacher or school official with 20 or more years of 
experience will confirm there is a real increase in autism and the numbers are rising” 
(Rimland, 2000). 
 Rimland’s views on biomedical treatments are just as radical. He was in full 
support of vitamin supplements, and the Gluten Free/Casein Free (GF/CF) diets. He felt 
the child with autism had a weak immune and digestive system, making the child more 
susceptible to environmental factors and having difficulty absorbing nutrients. After all 
his years of study, Rimland was convinced “autism is treatable” (testimony of Bernard 
Rimland, Before House Committee on Government Reform, 2000). 
Etiology: summary  
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 In review of the data from the FDA, CDC, congressional hearings, and scientific 
evidence, exposure to mercury in humans can result in immune, sensory, neurological, 
motor, and behavioral dysfunctions. These symptoms parallel the core deficits of 
autism. Whether, thimerosal latent vaccines are or are not the cause of autism, there 
are many unanswered questions as to the damage caused by thimerosal.  
Whatever the reason for the increase in autism, parents are agreeing with 
Rimland and are looking intently for alternative therapies and interventions to treat their 
child/ren. Throughout the years there have been many new, and some revision of old, 
therapies being used to treat children with autism; however, there is a lack of empirical 
research for these therapies. In order to better inform the parents there is a need for 
research in the increasing realm of biomedical therapies for children with autism 
(Roylance and Cohn, 2011). One area of growing interest with these parents is 
hyperbaric oxygen therapy.  
The analysis of possible etiologies of autism can be further evaluated and 
applied diagnostically through medical research. The premise of a toxic insult or viral 
overload as possible cause of autism would give necessity to findings of neurological 
abnormalities in people with autism that align with the medical research of effects of 
heavy metal poisoning and viral overload. The review of literature in the area of autism 
is necessary to understand further the possible etiology of autism and giving application 
to the correlations to possible treatments and educational plans.   
Brain Research--Hypoperfusion  
 When a typical person focuses on a task or generates speech, the brain is doing 
more work and there is an increase perfusion with the blood flow to the brain. This 
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increase in the blood flow to the brain supplies the brain with more oxygen and glucose, 
giving the cells their needed energy to perform their task. In autistic children, several 
studies have shown the opposite; these children actually have diminished blood flow to 
begin with, and when their brain is attempting to perform a task, such as generating 
speech or focusing, their blood flow does not increase giving them the needed oxygen 
and glucose the cells need (Fox, 1986, Muller, 1999). There is vasoconstriction instead 
of vasodilatation in the blood vessels. (Allen, 2003) This has been verified by studies 
that show an increase in p53 and a decrease in Bcl-2 in the brains of some children with 
autism. (Araghi-Niknam, 2003) Thus giving evidence for an indication of damage as a 
result of cerebral hypoxia (impaired oxygen delivery), resulting from the hypoperfusion. 
This is in correlation with the previously stated outcome of viral overload affecting the 
myelination process as a result of the ischemic effects from inflammatory process in 
which the vessels become inflamed and a downward spiral effects takes place resulting 
in cerebral hypoperfusion.    
 Cerebral hypoperfusion is simply decreased blood flow to the brain. There have 
been numerous studies in the medical literature demonstrating hypoperfusion in 
children with autism. “Bi-temporal hypoperfusion was confirmed in three independent 
groups of autistic children and provided the first robust evidence for localized 
dysfunction of the cerebral cortex in school-age children with primary autism.” (Boddaert 
and Zilbovicius 2002, p. 4) With newer upgraded brain-imaging cameras, detecting 
hypoperfusion in children with autism continues to become more defined.  One way this 
has been documented is through the use of SPECT scans.  One study conducted by 
Wilcox (2002) in the Department of Psychiatry at Texas Tech University Health 
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Sciences Center showed the hypoperfusion typically worsened with the age of the child, 
becoming quite profound in older children.  The diminished blood flow can be seen with 
a clear correlation to many core autistic symptoms/behaviors. For example, when the 
Thalamus has hypoperfusion the results are repetitive, self-stimulatory, and unusual 
behaviors. When hypoperfusion is found in the temporal lobes the results are desire for 
sameness and social/communication impairments, or in the cingulate gyrus the 
outcome is manifested in difficulty recognizing familiar faces. Reduction on cerebral 
blood flow in the amygdale results in social deficits such as the ability to feel emotion 
and understand other's emotions, and response to danger, and anxiety. (Ohnishi 
Matsuda, Hashimoto, Kunihiro, Nishikawa, Uema, and Sasaki, 2000)  
In order to look further into hypoperfusion, specifically in the temporal lobe, Zilbovicius, 
Boddaert, Belin, Poline, Remy, Mangin, J…. Samson (2000) conducted a study using a 
PET scan. The advancements in PET scans allowed the researchers to look for 
abnormalities in regional cerebral blood flow (rCBF).  The study consisted of twenty-one 
children with autism and ten non-autistic children. Later, twelve more children with 
autism were added to the study.  The children each had a PET scan and the image was 
reconstructed into 63 slices. The images were compared with t and Z statistics. The 
results revealed that the autistic group had significant hypoperfusion. There was no 
hypoperfusion in the comparison group. Regions with maximal hypoperfusion in the 
autistic group were centered in the left superior temporal gyrus, the right superior 
temporal gyrus, and in the right superior temporal sulcus (thought to process the human 
voice and coding facial expressions). These areas are involved in auditory processing. 
The left side generates an understanding of individual words; the right side deals with 
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pitch, melody and sound intensity. When this study was redone on an additional twelve 
children with autism, the results were within millimeters of the initial study. They 
concluded there could be a correlation between the hypoperfusion and the deficits 
found in children with autism. The temporal lobe dysfunction is related to sensory 
abnormalities, thought also to be central to the processing information about the world 
around us. The right superior temporal sulcus hypoperfusion may reflect the difficulties 
for the children to respond to voices and/or read faces.  
 Critchley, Daly, Bullmore, Williams, Amelsvoort, Robertson, Rowe, et al. (2000) 
colleagues published a study where they measured for changes in the cerebral blood 
flow when people with autistic disorder process facial expressions. Although high-
functioning individuals with autistic disorder have normal to superior range of 
intelligence; they have abnormalities in social communication and emotional behavior 
that tends to not improve over time.  The difficulty processing facial expressions of 
individuals with autism may be linked to the deficits in social behavior. The study used a 
Functional MRI (fMRI) to investigate brain activity in nine adults with autistic disorder 
and nine controls when consciously and unconsciously processing emotional facial 
expressions.  The individuals all met clinical diagnosis for Asperger syndrome or autism 
using ICD-10. Subjects were shown pictures with different facial expressions, they then 
rated the emotion. Their research showed significant differences between the subjects 
with autism and the control group in processing facial expressions. More specifically this 
would stem from abnormalities in the medial temporal lobe, striatum and insula when 
processing facial emotions.  This correlates with other studies that associate autism with 
cerebellar abnormalities. The amygdale (part of the brain that allows you to feel emotion 
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and understand other's emotions), part of the medial temporal lobe, is crucial to learning 
and representing the motivational meaning of stimuli. Critchley and colleagues 
concluded that while these findings give clues to the difficulty for individuals with autism 
to process facial expressions, it is not clear as to the origin of the deficits.  
 Similiar to Critchley, Ohnishi and colleagues also reported reduced cerebral 
blood flow in people with autism. They addressed the problem of people with autism 
having impaired functioning in communication and social interaction, abnormal 
response to sensory stimuli, and desire for sameness that is obsessive in nature. They 
hypothesize that these areas of deficits may be associated with perfusion in the medial 
prefrontal cortex and anterior cingulated gyrus of the brain. The study consisted of 
twenty-three children with infantile autism and twenty-six non-autistic mentally retarded 
children who underwent SPECT scans (single photon emission computed tomography). 
Just prior to the scan each patient received an intravenous injection that allowed the 
researcher to examine the brain perfusion.  The patients’ scores from the Childhood 
Autism Rating Scale (CARS) were compared with the areas of perfusion. The 
researchers discovered that there were decreases in regional cerebral blood flow in the 
patients with autism versus the non-autistic patients in the bilateral insula, superior 
temporal gyri, left inferior frontal gyrus, and left middle frontal gyrus.  For the patients 
with autism there were no areas of increase in cerebral blood flow. There was also a 
positive correlation between the reduction in cerebral blood flow in the hippocampus 
(the area for short term memory and the area that regulates emotions—including the 
gyrus which is very sensitive to oxygen deprivation) and the amygdale, which is part of 
the limbic system (almond-shaped clumps of cells deep in the brain, deals with 
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response to danger, anxiety, possible social interaction.)   In conclusion, there was a 
reduction of cerebral blood flow in children with autism compared to the non-autistic 
population. These areas are related to the deficits found in children with autism, for 
example the left anterior cingulated gyrus is associated with communication and social 
interaction deficits. There is also some question as to the correlation with the amygdale 
and social deficits.  People with frontal damage often show deficits related to the 
stereotypical and rigid behaviors often found in children with autism. These areas of 
reduced blood flow appear to be directly related to the deficits found in people with 
autism (Ohnishi, 2000).  
 Another study linked the reduction in cerebral blood flow to damage in the 
cerebellum that is often found in people with autism. Muller (1999) et al., conducted 
their study by doing PET scans on high-functioning adults with autism, with the premise 
that people with autism have deficits in language that according to former studies are 
directly related to deficits neurologically. With modern technology in brain imaging 
techniques, researchers can now study autism as a neurobiological disorder. Studies of 
normal adults show attention tasks activate the cerebellum; however, studies of patients 
with autism have shown the opposite. The researchers took five autistic adults and 
matched their gender matched with five controls. Cerebral blood flow was evaluated 
while subjects, autistic group versus control, were at rest, listening to tones, and 
listening to, repeating, and generating sentences using PET scans. The cerebral blood 
flow was evaluated on two elements, peaks and mean changes. They discovered that 
the subjects with autism showed reduced cerebellar activation during nonverbal auditory 
perception, suggesting cerebellar anomalies. This however was not related to motor 
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activities, as the deficit was not shown during sentence repetition. The autistic 
population versus the control group also showed reduced activation during acoustic 
stimulation in the auditory cortex. The autistic group showed bilateral weaker activations 
in the superior temporal. They also showed an absence of activation in the middle 
temporal.  However, in the left anterior cingulate gyrus (brodmann's 24/32) there was an 
increase in activation that was not seen in the control group. They concluded that their 
findings suggest the autistic group may have deficits in language developed in the 
cerebellum region. The brain mapping suggested the dominance for language might be 
reversed or reduced.  This might suggest early damage to areas of the brain, especially 
in the cerebellum.  
Brain Research--Inflammation  
 Vargas, Nascimbene, Krishnan, Zimmerman, and Pardo (2005) conducted a 
study at John Hopkins University on neurological conditions of autism by conducting 
autopsies on individuals with autism. They addressed the issue of people with autism 
having deficits in areas of communication, need for sameness, and social dysfunctions. 
These skills are directly related to specific areas of the brain. The question they sought 
to answer was do those with autism have increased neuroinflammation in areas related 
to those deficits. They conducted autopsies and evaluated brain tissue from eleven 
people with autism for inflammation and tissue contents. The cerebrospinal fluid was 
also evaluated. The control group was seven patients with frozen tissue. They also 
collected cerebrospinal fluid from tissues of six living patients with autism. There was 
evidence of neuroinflammation, or inflammation of the brain. The results showed 
chronic neuroinflammation in the patients with autism. Vargas (2005) found the common 
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trait of all the patients with autism was a chronic inflammatory process affecting both the 
brain and immune system functioning. The cerebellum showed considerable affects. It 
is not clear as to how the brain became affected, neurotoxins was one area considered. 
The researchers expressed they did not feel the inflammation occurred exclusively 
during the prenatal development, but rather ongoing chronic neuroinflammation 
involving both microglia and astrogli, (cells dealing with immune system and 
neurological tissues). They concluded that there is chronic neuroinflammation in 
patients with autism. They recommend therapeutic interventions dealing with the 
inflammation as a possible treatment for autism. 
 Neuroinflammation was also addressed as a possible result of enlarged activated 
astroglia. Aschner, Allen, Kimelberg, LoPachin, and Streit, (1999) "observed swelling of 
astrocytes is associated with a nearly 50% decrease in the average capillary lumen as 
measured by electron microscopy, which will result in decreased blood flow because the 
flow of red blood cells is impeded" (p. 159 ). Helt (2008) brings that one step further to 
show the inflammation results in increasing difficulty in the body's ability to eliminate 
waste products from the blood system, "hence impairing the cellular activities 
associated with neural activity and synchronization" (p.359), correlating to Just (2004) 
and Castelli's (2002) research. As a result, with time, different areas of the brain 
develop the inability to work together (Muller 2007). Once again, Helt stated, "If this 
inflammation could be controlled early in life, it might prevent such atypical development 
from taking place" (p. 359).  
Multiple studies have confirmed the neuroinflammation of children with autism.  
The inflammation in the brain causes edema, which increases the area between the 
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cells, and therefore, could increase the amount of fluid inside the brain cells. Two 
studies confirmed this through a functional MRI (fMRI) (Hendry, et al., 2006). The 
question with children affected by autism may not be if they demonstrate 
neuroinflammation, but why they have the inflammation in the first place. 
 Zerrate, Pletnikov, Connors, Vargas, Seidler, Zimmerman (2007) addressed the 
issue of why the neuroinflammation by researching the link between the inflammation, 
behavioral abnormalities and Terbutaline, a preterm labor drug. The researchers 
hypothesized a correlation between prenatal drugs or chemical exposure could be a 
cause of autism. The study consisted of giving pregnant rats Terbutaline on selected 
days. After the pups were born, they were analyzed for behavior. Later they were 
anesthetized and the brains removed. The brains were then studied. The results 
demonstrated increased hyperactivity in the rats exposed to Terbutaline. There was 
also neuroinflammation. The most critical times of exposure were the second to third 
trimester of human brain development. They concluded a chemical exposure could 
affect the growing fetus in behavioral issue and neuroinflammation. This many 
contribute to the increase in the incidents of autism (Zerrate, et al., 2007). 
Herbert and Anderson (2008) suggest viruses or heavy metals infiltrating the 
body during early development as possible causes for the neuroinflammation. The 
body’s inability to eliminate the virus overload or heavy metals from the body may 
stimulate an oxidative stress response which may lead to neuroinflammation, leading to 
deficits with brain synchronization. These early immunological insults to the brain may 
thus be core to the deficits seen in autism.   
 
  76 
 
 
 
Brain Research—Synchronization 
 Some more resent research is taking the brain research a step further by looking 
at how the brain of the autistic child works in synchronization. Just, et al. (2004) looked 
specifically at the brain’s synchronization during a sentence comprehension task. They 
knew that high-functioning individuals with autism often display enhanced cognitive 
functioning with high vocabulary, yet they show a deficit in processing verbal 
instructions. The researchers hypothesized, “autistic participants may rely more on an 
enhanced word-processing ability (which would be indicated by more-than-normal 
activation in Wernicke’s area), and rely less on integrating processes that bring the 
words of a sentence together into an integrated syntactic and semantic structure 
(indicated by less-than-normal activation in Broca’s area)” (Just, 2004, p. 1812). The 
researchers conducted the study with seventeen high-functioning autistic patients and 
seventeen normal participants. They were each given fMRI while asked questions that 
required sentence comprehension tasks. The participants were asked to press a button 
on either their right or left hand with the correct response to the question. Then the data 
was analyzed looking specifically at the left inferior frontal gyrus (LIFG) (Broca’s area) 
and the left superior and middle temporal gyrus (LSTG) (Wernicke’s area) and their 
synchronization. They discovered the autistic patients had a lower degree of 
synchronization between LIFG and the LSTG. The autistics showed less activation in 
the left inferior frontal gyrus versus the control group; however, they showed more 
activation in the left posterior superior temporal gyrus. The researchers concluded that 
the reduction in synchronization may give explanation for the deficits with auditory 
comprehension. The possible reason for this may be the autistic brain puts more 
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emphasis on the individual words and details, with difficulty in higher-level abstraction, 
instead of comprehending the entire passage. The lack of synchronization may also 
account for social deficits in with the ability to integrate different types of information at 
abstract levels such as facial expressions, personal intent, and pragmatics (Just, 2004). 
Another study conducted by Castelli (2002), intergraded synchronization with a 
reduction in cerebral blood flow. Again the research team looked at the functional 
deficits of a person with autism and compared it to the actual diagnostic deficits 
happening in the brain. They used a comparison study with ten adults diagnosed with 
autism and ten people in the control group made up of students and staff recruited from 
a university. The participants were shown twelve different brief animations, four different 
animations from three different types. After viewing, the subjects were questioned about 
what was happening in the animation. Their descriptions were coded in regards to 
intentionality, appropriateness, and length. Each subject underwent twelve scans, both 
PET and MRI, on the same day. The results were analyzed using software from the 
Wellcome Department of Cognitive Neurology in London, United Kingdom. The results 
demonstrated a direct comparison on the two groups there was a significant reduction in 
blood flow velocity in the autism subjects in the basal temporal area, superior temporal 
sulcus, and the medial prefrontal area. The extrastriate regions (brodmann's 18/19) 
activated at the same rate; however, they were not interacting appropriately with the 
mentalizing network that showed a reduction. They concluded that people with autism 
do have impaired brain function with reduction in cerebral blood flow and lack of 
connectivity, especially evident when subject is mentalizing.  One area of possible origin 
is the Amygdala (Castelli, 2002). 
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 The pathophysiology of children with autism appears to include a number of 
different brain abnormalities. However, the area that is most often referred to as the site 
of the most abnormality is the cerebellum. The cerebellum damage shows consistent 
area for inflammation and also cell damage. One cell in particular is the Purkinje cell. 
Not only do multiple studies show a reduction in the Purkinje cell, but also Fatemi and 
colleagues have shown not only a reduction in the number of Purkinje neurons, but also 
a reduction in size (Fatemi, 2001). Chronic, ongoing process of neuroinflammation is a 
likely source for the reduction of the Purkinje Cells. Based on the research of Vargas 
and colleagues the findings of immune responses in the cerebellum were closely 
associated with degenerating Purkinje Cells, granule cells, and axons. In correlation to 
thimerosal, a side-effect of mercury poisoning is reduction in the number of Purkinje 
Cells (Sorensen, Larsen, Eide, and Schionning, 2000, Choi, Lapham, Amin-Zaki, 
Saleem, 1978).  
In summary as a relationship to hyperbaric oxygen therapy 
      Brain deficits in the area of hypoperfusion/decreased cerebral blood flow, reduction 
of the Purkinje cells, inflammation, and lack of synchronization is common research in 
the area of autism. These deficiencies are clearly linked to the deficits found in people 
with autism. Neurological effects of mercury on the brain are in the amygdale, 
hippocampus, basal ganglia, cerebral cortex, damages Purkinje and granule cells in the 
cerebellum, paralleling the damage found in the autistic brain. 
The neurological abnormalities manifest as deficits in cerebral blood flow, 
hypoperfusion, neuroinflammation, and lack of brain synchronization. This is important 
to understand in order to begin to find ways to treat people with autism, and understand 
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the theory behind the treatment. This is reflective in the treatment of hyperbaric oxygen 
therapy. When a person receives hyperbaric oxygen therapy the blood flow in the brain 
is increased, and hypoxia and inflammation are reduced. There is also speculation of 
the mucous lining in the gut healing with hyperbaric oxygen therapy. Hence, it is 
reasonable to recognize how hyperbaric oxygen therapy may decrease neurological 
deficits and reduce symptoms of autism.  
Benefits from hyperbaric oxygen therapy may not be limited to the child's early 
years. In a study by Guy (2007) called "Reversal of neurological defects in a mouse 
model of Rett syndrome" he demonstrated reversing symptoms associated to Rett's 
Syndrome was shown through biological treatment. The researchers activated MeCP2 
in adult mice affected with Rett's Syndrome. The results were phenotypic reversal of the 
syndrome. Guy et al. demonstrated defective neurons have the ability to be repaired 
into adulthood, contrary to popular belief of the damage being permanent after the 
"critical period."   
 No matter the cause of the neuroinflammation the effects can be devastating. 
However, hyperbaric oxygen therapy may be one answer to addressing the neurological 
deficits in autism to be treatable by reducing the inflammation.  
 The exact reasons hyperbaric oxygen therapy helps children with ASD are still 
being researched; however, there are some clear correlations one can make with the 
data from current research.  The occurrence of inflammation in the brain and 
gastrointestinal tract of these children has been shown to be significant. There have 
been several studies of treating the inflammation with drugs such as corticosteroids, 
minocycline and non-steroidal anti-inflammatory drugs, however, the negative side 
  80 
 
 
 
effects make the use of these drugs undesirable. The effects of hyperbaric oxygen 
therapy, promoting the growth of new capillaries, increasing the production of the body’s 
stem cells, decreasing swelling and inflammation, increasing the body’s ability to fight 
infections, clearing and deactivating toxins and metabolic waste products from the body, 
reduce these negative symptoms. Therefore, it is understandable why the results from 
the initial studies of treating children with autism in hyperbarics are resulting in positive 
outcomes. Hyperbaric oxygen therapy is well known as an anti-inflammatory, and has 
virtually no negative side effects.  With the known effects of hyperbaric oxygen therapy 
and the inflammation found in children with autism, there warrants continued studies of 
treating children with autism in hyperbaric oxygen therapy. The risk-benefit analysis is 
strongly in favor of pursuing hyperbaric oxygen therapy as a potential therapy for 
autism. 
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CHAPTER 3 
Methodology 
Participants 
All children receiving hyperbaric oxygen met Michigan Rule 340.1715: Autism 
Spectrum Disorder Eligibility for autism (addendum A) and have an Individual Education 
Plan (IEP) for Autism filed with their school system. The children will be enrolled in an 
educational environment that supports the autism diagnosis. The geographic area will 
be Metropolitan Detroit area. The children’s parents have chosen to do hyperbaric 
oxygen therapy at a private clinic with no relationship to the research. In order to 
evaluate eligibility, the participants will be asked to answer question before participation 
can be determined. The questionnaire is found in the Appendix D.  
Eligibility Criteria 
1. Eligibility for autism was determined by a prior comprehensive evaluation 
conducted by a Multi-Disciplinary Evaluation Team (MET) that included ALL 
of the following:  
a. A psychologist or psychiatrist  
b. An authorized provider of speech & language per Rule 340.1745(d).  
c. A school social worker. 
2. The student has a current MET that states they are eligible for services under 
the area of autism. 
3. Participants must agree to completing The Autism Treatment Evaluation 
Checklist (ATEC) within 30 days prior to the child’s first hyperbaric treatment. 
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4. Participants must agree to a release of information from the student’s 
classroom teacher to fill out the ATEC prior and post treatment.  
5. Child’s teacher must be able to complete the pre and post test, ATEC, within 
30 days prior and post of their final, fortieth hyperbaric oxygen treatment. 
6. Participants must be able to complete the post test, ATEC within 30 days of 
their final hyperbaric oxygen therapy treatment. 
7. Participant’s child will be hyperbaric oxygen therapy treatment naive prior to 
treatment, meaning they have not undergone hyperbaric oxygen treatment 
prior to this set of treatments. 
8. Participant’s child must be able to complete forty sessions of hyperbaric 
oxygen therapy within eleven weeks of starting treatment, doing five 
treatments per week. A typical set of forty treatments is completed in eight 
weeks. The extended three weeks allows for illness or vacation time. 
Exclusion Criteria 
 
1. Participant’s child does not meet the MET criteria for special education services for 
autism 
2. Participant’s child has previously treated in hyperbaric oxygen therapy.  
3. Participants have not signed a release of information to contact the student’s teacher. 
Human Investigation Committee 
The study was conducted with approval of the Wayne State University Human 
Investigation Committee. Permission to conduct the research for the study was obtained 
from a parent and teacher of each child in the study prior to admittance into the study.  
Participation in the study was voluntary. Respondents were assured that their 
  83 
 
 
 
responses were completely anonymous and there was no personal identification 
information included with any returned responses. There was no compensation for 
participation in the study. 
Technique  
A combination of qualitative and quantitative techniques was used for data 
analysis to establish continuity between the statistical analysis and the narrative 
documentation of the parents and techs. The Autism Treatment Evaluation Checklist 
(ATEC), a Likert-type scale, was used for the quantitative portion of the study. A parent 
and teacher of each participant filled out the ATEC prior to the child starting their 
treatment and after the completion of their treatment. All five children were able to have 
the ATEC completed by a parent and teacher. The ATEC evaluates children with autism 
with four categories: speech/language/communication, sociability, sensory/cognitive 
awareness, and health/physical/behavior. Declining scores on each scale indicate 
clinical improvements. Dive logs, notations from the Certified Hyperbaric Technologist 
(CHT) and parents input or journal were used for the qualitative portion. 
Statistical analysis  
 The ATEC’s scores will be compared using Pearson correlation coefficient to 
measure interrater reliability between parents’ scores and the ATEC and teachers’ 
scores. A combination of qualitative and quantitative techniques will be used for data 
analysis to establish continuity between the statistical analysis and the narrative 
documentation of the parents and techs. A t-test with Paired Samples Statistics data 
analysis will be used to compare the pretest and post test scores. The dependent 
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variable is the changes in the student as measured by the ATEC. Nominal alpha will be 
set at 0.05. 
Assumptions:  
1. Normal Distribution: The dependent variable should be normally distributed within 
groups.    
2. Observations are independent from one another, teacher and parent 
3. Homogeneity of Variances: Homogeneity of variances assumes that the 
dependent variables exhibit equal levels of variance across the range of predictor 
variables.  
4. Homogeneity of Variances and Covariances: The homogeneity of variances 
assumption described earlier also applies. However, since there are multiple 
dependent variables, it is also required that their intercorrelations (covariances) 
are homogeneous across the cells of the design.  
Instruments Used in Data Collection 
 The Autism Treatment Evaluation Checklist (ATEC) was designed by Dr. Bernard 
Rimland and Dr. Stephen Edelson from the Autism Research Institute. The purpose of 
the evaluation was not to diagnose autism, but rather “to help researchers evaluate the 
effectiveness of various treatments for autistic children and adults and to help parents 
determine if their child benefited from the treatment. Parents and teachers use the 
ATEC to monitor or track how well their children are progressing over time” (Edelson, 
2010). 
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 The ATEC evaluation consists of 4 subtest: speech/language/communication (14 
items), sociability (20 items), sensory/cognitive awareness (18 items), 
health/physical/behavior (25 items).  
Instrument Reliability and Validity  
 According to the Autism Research Institute the internal consistency of the ATEC 
was evaluated using split-half reliability test on 1,358 completed ATECs. The internal 
consistency was .94. The subscale reliabilities were: Scale I Speech .920, Scale II 
Sociability .836, Scale III Sensory/Cognitive Awareness .875, Scale IV 
Health/Physical/Behavior .815, Total ATEC Score .942.  
Methods/Procedures Used 
 Participants will be children whose parents have chosen to do forty sessions of 
hyperbaric oxygen therapy in a private setting at 2.0 ata (atmospheres absolute, 14.7 
psig, or 33 feet of sea water). At the time the parents sign up for therapy they will be 
asked if they would agree to be part of a study. The participants are not consenting to 
doing hyperbaric oxygen therapy, rather consenting for the child's parent/s and teacher 
to fill out pre and post evaluation, and to use the data.  
 The participants will be prescreened to see that they meet the initial criteria and 
exclusion requirements. The participants will be interviewed to assure they understand 
the assessment being used. It will be explained to the participants the role their child’s 
teacher will play by evaluating their child also before the set of treatments and after the 
completion. If they agree a release will be signed to contact the child’s teacher. The 
teacher will be contacted to see if they are willing to fill out the evaluation on the child.  
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 The Autism Treatment Evaluation Checklist (ATEC) is conducted by filling out a 
Likert style questioner. A copy of the questions is found in Appendix D. The Autism 
Treatment Evaluation Checklist (ATEC) will be completed by the parent/s of the child 
prior to their treatment. The evaluation will also be given to the child’s teacher to be 
filled out prior to evaluation. A survey/questionnaire will be conducted with the caretaker 
to verify the participant meets the criteria. (Appendix D).  
1. Participants will be referred to researcher by Oxford Hyperbaric Oxygen Therapy 
Center. 
a. Oxford Hyperbaric Oxygen Therapy Center will ask the parents when they 
enroll their child into the therapy if they are interested in having their child be part 
of a research study on autism and hyperbaric oxygen therapy.  
b. If the parents verbalize they are interested they will be given a release to 
have the researcher contact them. 
c. Parents will be contacted by the researcher and the questionnaire will be 
given to them over the phone.  
d. If the child qualifies the parents will be given a release of information form in 
order for the researcher to contact the child’s teacher. 
e. The teacher will be contacted and asked if he or she will agree to filing out an 
evaluation about their student.  
f. If the teacher agrees to fill out the evaluation, the child will be part of the 
research study. 
g. The parents and teacher will be asked fill out a pre-evaluation by circling the 
letter that best describes the current level of the participant.  
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h. At dive number 37 the parents and teacher will be contacted to know the post 
evaluation will soon need to be filled out. They will be contacted soon as to the 
exact date.  
i. The day the child completes dive forty the parents and teacher will be 
contacted to ask to fill out a post-evaluation of the student. This should be 
completed within five days of the child’s 40 dive completion. 
ATEC Scoring 
  The ATEC test uses a simple Internet scoring procedure that automatically 
calculates subscale scores and a summary score from the ATEC, which are weighted 
according to the response and the corresponding subscale.  The Autism Treatment 
Evaluation Checklist (ATEC) is not copyrighted and may be used free of charge by any 
researcher.  The higher the subscale and total scores, the more impaired the subject. 
Alpha will be set at .05. Due to the fact this is an observational study; the number of 
participants will be small.  
Summary of data (Appendix E) 
Pretest/Post-test  sample (Appendix F) 
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Chapter 4 
Results 
 The purpose of the study was to obtain data on the efficacy of treating a child 
with autism in hyperbaric oxygen therapy by assessing changes in 
speech/language/communication, sociability, sensory/cognitive awareness, and 
health/physical/behavior.  
 The chapter presents the results of the findings related to the study’s specific 
research questions. 
Demographic Characteristics of Participants 
There were five children in the study, two female and three male. All five 
participants lived in the Metropolitan Detroit Area. The ages of the participants were 
between 2.9 and 7.2 years of age at the start of their treatment, with the mean age 
being 4.6. The participants began their forty treatments in hyperbaric oxygen therapy 
between February 17, 2011 and March 4, 2011. They completed their treatments 
between March 28, 2011 and May 2, 2011. All participants were able to complete the 
study design of forty treatments.  
Reliability Indicators of internal consistency 
 The Pearson correlation coefficient was used to measure interrater 
reliability between parent’s scores and the ATEC and teacher’s scores. The Pearson 
correlation coefficient measures the strength of a linear association between two 
variables. The pretest for Speech/Language/Communication had a strong positive 
correlation of .957, which was statistically significant (p= .011), the post test for the 
same was .948 (p= .014). In the area of Sociability the pretest was .748 (p= .116), and 
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post test was .852 (p= .067), both showing a strong positive correlation but are not 
statistically significant due to the obviously small sample size. For sensory/cognitive 
awareness the pretest was again a strong positive correlation of a .829 (p= .083), the 
post test was .853 (p= .066), which are also obviously not statistically significant due to 
the small sample size.  In the area of health/physical/behavior, the pretest showed a 
strong positive correlation of .833 (p= .080) and the post test was positive correlation of 
.646 (p= .239), which are interpreted as the previous two measures. When combining 
the subcategories, the teacher pre correlated to the teacher post had a strong positive 
correlation of .941 (p= .017), which was statistically significant. Lastly, the post test 
teacher correlated to the parents again showed a strong positive correlation of .847 (p= 
.071) which was not statistically significant due to sample size.  
 
Correlations between Speech/Language/Communication teacher and parent pre test 
Correlations 
 
SLC Teacher 
Pre SLC Parent Pre 
SLC Teacher Pre Pearson Correlation 1 .957* 
Sig. (2-tailed) 
 
.011 
N 5 5 
SLC Parent Pre Pearson Correlation .957* 1 
Sig. (2-tailed) .011 
 
N 5 5 
*. Correlation is significant at the 0.05 level (2-tailed). 
Table 3   
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Correlations between Speech/Language/Communication teacher and parent post test 
Correlations 
 
SLC Teacher 
Post 
SLC Parent 
Post 
SLC Teacher Post Pearson Correlation 1 .948* 
Sig. (2-tailed) 
 
.014 
N 5 5 
SLC Parent Post Pearson Correlation .948* 1 
Sig. (2-tailed) .014 
 
N 5 5 
*. Correlation is significant at the 0.05 level (2-tailed). 
Table 4 
 
Correlations between Sociability teacher and parent pretest 
Correlations 
 SO Teacher Pre SO Parent Pre 
SO Teacher Pre Pearson Correlation 1 .784 
Sig. (2-tailed) 
 
.116 
N 5 5 
SO Parent Pre Pearson Correlation .784 1 
Sig. (2-tailed) .116 
 
N 5 5 
  Table 5 
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Correlations between Sociability teacher and parent post test 
Correlations 
 
SO Teacher 
Post SO Parent Post 
SO Teacher Post Pearson Correlation 1 .852 
Sig. (2-tailed) 
 
.067 
N 5 5 
SO Parent Post Pearson Correlation .852 1 
Sig. (2-tailed) .067 
 
N 5 5 
 
   
  Table 6 
 
Correlations between Sensory/Cognitive teacher and parent pretest 
Correlations 
 
COG Teacher 
Pre COG Parent Pre 
COG Teacher Pre Pearson Correlation 1 .829 
Sig. (2-tailed) 
 
.083 
N 5 5 
COG Parent Pre Pearson Correlation .829 1 
Sig. (2-tailed) .083 
 
N 5 5 
  Table 7 
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Correlations between Sensory/Cognitive teacher and parent post test 
Correlations 
 
COG Teacher 
Post COG Parent Post 
COG Teacher Post Pearson Correlation 1 .853 
Sig. (2-tailed) 
 
.066 
N 5 5 
COG Parent Post Pearson Correlation .853 1 
Sig. (2-tailed) .066 
 
N 5 5 
 Table 8 
 
Correlations between Health/physical/behavior teacher and parent pretest 
Correlations 
 
PHY Teacher 
Pre PHY Parent Pre 
PHY Teacher Pre Pearson Correlation 1 .833 
Sig. (2-tailed) 
 
.080 
N 5 5 
PHY Parent Pre Pearson Correlation .833 1 
Sig. (2-tailed) .080 
 
N 5 5 
 Table 9 
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Correlations between Health/physical/behavior teacher and parent post test 
Correlations 
 
PHY Teacher 
Post PHY Parent Post 
PHY Teacher Post Pearson Correlation 1 .646 
Sig. (2-tailed) 
 
.239 
N 5 5 
PHY Parent Post Pearson Correlation .646 1 
Sig. (2-tailed) .239 
 
N 5 5 
 Table 10 
 
Correlations between teachers and parents 
Correlations 
 Tr Pr 
Tr Pearson Correlation 1 .941* 
Sig. (2-tailed) 
 
.017 
N 5 5 
Pr Pearson Correlation .941* 1 
Sig. (2-tailed) .017 
 
N 5 5 
 Table 11 
 
 
 
Correlation between teacher pretest and parent pretest 
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Correlations 
 tpo Ppo 
tpo Pearson Correlation 1 .847 
Sig. (2-tailed) 
 
.071 
N 5 5 
ppo Pearson Correlation .847 1 
Sig. (2-tailed) .071 
 
N 5 5 
 Table 12 
The teacher’s responses and parent’s responses reflects the changes in scores 
between the pre and post testing as scored by the teacher and parents. The parents 
calculate an 11.08% mean improvement and the teachers a 9.91% mean improvement. 
The parent’s largest area of improvement was in the area of health/physical/behavior 
with a 17.61%, while the teachers largest are of improvement was the area of 
Sensory/Cognitive Awareness with a 14.29%. All areas showed a mean average with 
improvements.  
Mean averages of all areas in percentage.  
 
Mean Score 
Before HBOT 
Parents 
Mean Score 
After HBOT 
Parents 
Percentage of 
Improvement 
Mean Score 
Before HBOT 
Teacher 
Mean Score 
After HBOT 
Teacher 
Percentage of 
Improvement 
Speech/Lang/ 
Communication 15.8 14.8 6.33% 17.4 15.6 10.34% 
Sociability 15.2 13.6 10.53% 20.2 19.4 3.96% 
Sensory/Cog/ 
Awareness 14.6 14.0 4.11% 23.8 20.4 14.29% 
Health/Physical/ 
Behavioral 28.4 23.4 17.61% 27.4 24.6 10.22% 
TOTAL 74.0 65.8 11.08% 88.8 80.0 9.91% 
Table 13 
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                                                                                                   Figure 9   
 
                                                                                                          Figure 10 
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Data analysis 
A t-test with Paired Samples Statistics data analysis was performed with SPSS 
(Statistical Package for the Social Sciences Personal Computer) software. The Paired-
Samples Test or the dependent t-test compares the means between two related groups 
on the same continuous variable. It provides relevant descriptive statistics. 
Data from the ATEC was entered into the SPSS software in order to form a t-test 
calculation.  Despite the pattern of improvement for all children, with respect to the t-
test, there reveals only one significant difference between the pre and post test, most 
likely due to the small sample size. However, even with the small sample size, the 
teacher checklist revealed a statistical significant difference in the area of 
sensory/cognitive awareness according to the Pearson t-test. Although not a close 
runner up, the next closest score would be in the teacher’s rating of 
speech/language/communication.  
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Paired samples correlations Pretest and Post test 
 
 
 
                
 
 
 
 
 
 
 
 
                                                                                  Table 14 
 
 
 
 
 
 
 
 
 
Paired Samples Correlations 
 N Correlation Sig. 
Pair 1 SLC Teacher Pre & SLC 
Teacher Post 
5 .970 .006 
Pair 2 SO Teacher Pre & SO 
Teacher Post 
5 .741 .152 
Pair 3 COG Teacher Pre & COG 
Teacher Post 
5 .947 .015 
Pair 4 PHY Teacher Pre & PHY 
Teacher Post 
5 .979 .004 
Pair 5 SLC Parent Pre & SLC 
Parent Post 
5 .987 .002 
Pair 6 SO Parent Pre & SO Parent 
Post 
5 .923 .025 
Pair 7 COG Parent Pre & COG 
Parent Post 
5 .887 .045 
Pair 8 PHY Parent Pre & PHY 
Parent Post 
5 .869 .055 
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Paired Sample Statistics with T-Test 
Paired Samples Statistics 
 Mean N Std. Deviation Std. Error Mean 
Pair 1 SLC Teacher Pre 17.4000 5 8.26438 3.69594 
SLC Teacher Post 15.6000 5 6.73053 3.00998 
Pair 2 SO Teacher Pre 20.2000 5 5.93296 2.65330 
SO Teacher Post 19.4000 5 6.34823 2.83901 
Pair 3 COG Teacher Pre 23.8000 5 6.22093 2.78209 
COG Teacher Post 20.4000 5 7.23187 3.23419 
Pair 4 PHY Teacher Pre 27.4000 5 17.03819 7.61971 
PHY Teacher Post 24.6000 5 12.11610 5.41849 
Pair 5 SLC Parent Pre 15.8000 5 7.19027 3.21559 
SLC Parent Post 14.8000 5 8.40833 3.76032 
Pair 6 SO Parent Pre 15.2000 5 7.19027 3.21559 
SO Parent Post 13.6000 5 6.22896 2.78568 
Pair 7 COG Parent Pre 14.6000 5 6.42651 2.87402 
COG Parent Post 14.0000 5 6.40312 2.86356 
Pair 8 PHY Parent Pre 28.4000 5 18.87591 8.44156 
PHY Parent Post 23.4000 5 7.43640 3.32566 
   
          Table 15 
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Pair sample test pretest to post test mean 
 
 
 
 
 
 
 
 
 
 
 
 
                    Table 16 
     
 
 
 
 
 
 
 
 
Paired Samples Test 
 
Paired Differences 
Mean Std. Deviation Std. Error Mean 
Pair 1 SLC Teacher Pre - SLC 
Teacher Post 
1.80000 2.38747 1.06771 
Pair 2 SO Teacher Pre - SO 
Teacher Post 
.80000 4.43847 1.98494 
Pair 3 COG Teacher Pre - COG 
Teacher Post 
3.40000 2.40832 1.07703 
Pair 4 PHY Teacher Pre - PHY 
Teacher Post 
2.80000 5.71839 2.55734 
Pair 5 SLC Parent Pre - SLC 
Parent Post 
1.00000 1.73205 .77460 
Pair 6 SO Parent Pre - SO Parent 
Post 
1.60000 2.79285 1.24900 
Pair 7 COG Parent Pre - COG 
Parent Post 
.60000 3.04959 1.36382 
Pair 8 PHY Parent Pre - PHY 
Parent Post 
5.00000 12.94218 5.78792 
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Paired Samples Test Pretest Post test (2-tailed) 
 
 
 
 
 
 
 
   
 
 
 
 
                           Table 17 
 
 
 
 
 
 
 
 
 
Paired Samples Test 
 df Sig. (2-tailed) 
Pair 1 SLC Teacher Pre - SLC 
Teacher Post 
4 .167 
Pair 2 SO Teacher Pre - SO 
Teacher Post 
4 .708 
Pair 3 COG Teacher Pre - COG 
Teacher Post 
4 .034 
Pair 4 PHY Teacher Pre - PHY 
Teacher Post 
4 .335 
Pair 5 SLC Parent Pre - SLC 
Parent Post 
4 .266 
Pair 6 SO Parent Pre - SO Parent 
Post 
4 .269 
Pair 7 COG Parent Pre - COG 
Parent Post 
4 .683 
Pair 8 PHY Parent Pre - PHY 
Parent Post 
4 .436 
  101 
 
 
 
Paired Samples Test with t 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 18 
The Wilcoxon Signed Ranks Test was also performed using the SPSS software.  This is 
a nonparametric test equivalent to the dependent t-test. It is used to examine difference 
in means between two sets of scores that come from the same participants when the 
underlying distribution cannot be asserted to be normally distributed. The comparison 
data that was used was the pretest and post test of the individual students, giving a 
natural pair. If the null hypothesis is true there would be no difference and the rank 
sums for positive and negative ranks would be the same. Because the test is based on 
Paired Samples Test 
 
Paired Differences 
t 
95% Confidence Interval of the 
Difference 
Lower Upper 
Pair 1 SLC Teacher Pre - SLC 
Teacher Post 
-1.16443 4.76443 1.686 
Pair 2 SO Teacher Pre - SO 
Teacher Post 
-4.71109 6.31109 .403 
Pair 3 COG Teacher Pre - COG 
Teacher Post 
.40968 6.39032 3.157 
Pair 4 PHY Teacher Pre - PHY 
Teacher Post 
-4.30032 9.90032 1.095 
Pair 5 SLC Parent Pre - SLC 
Parent Post 
-1.15063 3.15063 1.291 
Pair 6 SO Parent Pre - SO Parent 
Post 
-1.86778 5.06778 1.281 
Pair 7 COG Parent Pre - COG 
Parent Post 
-3.18657 4.38657 .440 
Pair 8 PHY Parent Pre - PHY 
Parent Post 
-11.06984 21.06984 .864 
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the rank order of differences versus the actual value of the differences, distributional 
assumption is avoided, although assumption is assumed that the distribution of the 
differences is symmetric.  
Wilcoxon Signed Ranks Test 
Ranks 
 N Mean Rank Sum of Ranks 
post - pre Negative Ranks 4a 3.25 13.00 
Positive Ranks 1b 2.00 2.00 
Ties 0c 
  
Total 5 
  
a. post < pre 
b. post > pre 
c. post = pre 
                        Table 19 
Wilcoxon Signed Ranks Test continued 
Test Statisticsb 
 post – pre 
Z -1.483a 
Asymp. Sig. (2-tailed) .138 
a. Based on positive ranks. 
b. Wilcoxon Signed Ranks Test 
        
Table 20 
The Wilcoxon Signed Ranks Test showed that a 40 treatment hyperbaric oxygen 
therapy course did not elicit a statistically significant change in (list 4 areas) individuals 
with autism (Z = -1.483, P = 0.138).  
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Analysis of Research Questions One through Four 
For question number one, “is there increase an increase in 
speech/language/communication of an autistic child who has received hyperbaric 
oxygen therapy using the Autism Treatment Evaluation Checklist as a measurement 
tool?” the answer would be yes. The parents reported a 6.33% of improvement and the 
teacher reported a 10.34% of improvement. This is also evidenced by the narrative 
report from the parent. For question number 2, “is there an increase in sociability of an 
autistic child who has received hyperbaric oxygen therapy using the Autism Treatment 
Evaluation Checklist as a measurement tool?” the answer would be yes. The parents 
reported a 10.53% of improvement and the teachers reported a 3.96% of improvement. 
For question number three, “is there an increase in sensory/cognitive awareness of an 
autistic child who has received hyperbaric oxygen therapy using the Autism Treatment 
Evaluation Checklist as a measurement tool?” the answer would be yes. The parents 
reported a 4.11% of improvement and the teachers reported a 14.29% of improvement. 
Lastly, for question number four, “is there an increase in the health/physical/behavior of 
an autistic child who has received hyperbaric oxygen therapy using the Autism 
Treatment Evaluation Checklist as a measurement tool?” the answer is yes. The 
parents reported a 17.61% of improvements and the teachers reported a 10.22% of 
improvements. 
Qualitative 
 The CHT recorded notes from parent/s and their observations at the time of each 
child’s dive. Also, several parents filled out a journal and/or summary of their child’s 
changes. The logs and journals are in Appendix G Improvements noted were very much 
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in line with the improvements documented on the ATEC. Some of the comments for T-
TW, “more alert, more interest in people and new things presented to him, 
comprehension, now following simple one-step commands consistently and some two 
step commands, more speech and in appropriate context.” T-JC’s parent wrote in a 
journal daily. Some of the comments were, “playing with dog better, eating better, 
saying prayers slower, not as hyper, loving, playful and not yelling as much, went out to 
lunch and did best ever in a restaurant, using brother’s DS first time ever, first 6 word 
sentence, no more yelling” T- SC’s parents and CHT’s notes, “Increase in independent 
behavior, increase in eye contact, increased focus, more smiles, focus and 
conversation.  
T-AO’s parents and CHT’s notes, “much calmer at home and less temper, able to 
sleep at night after the very first dive, she was not sleeping before,  she slept all night 
long, no tantrums with her coat, no longer climbing the walls and pulling cabinet doors 
off the hinges, no longer plays as rough, less bruises on her legs.” By dive 33, “her 
eating is back to normal, sleeping back to normal, no waking up, teacher said she said 
her name, she has a comprehension of emotion and mimics from the DVD.” The CHT 
and parents notes for S-DR, “has been more relaxed for a week or so, attending church 
has been more pleasant as S- DR has been calmer, engaging visually and a little more 
attentive.” The parents overall made positive comments in the four areas of question: 
speech/language/communication, sociability, sensory/cognitive awareness, and 
health/physical/behavior.  
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Parent’s comments could be put into the five categories below: cognitive, 
speech, affect/behavior, calmer, more alert/eye contact. These were all positive 
comments by the child’s parent.  
 
Parent Observations: 
 Cognitive Speech Affect/behavior Calmer Alert/eye 
contact 
T-TW X X X X X 
T-JC X X X X  
T-SC X X  X X 
T-AO X X  X  
S-DR X   X  
          Table 21 
The parents overall all commented on positive improvements with cognitive issues. 
From the parents perspective this was seen by such things as following verbal 
directions, reading, playing with puzzles, and playing video games. All parents also 
commented on the child being calmer. This was the most popular and consistent 
comment given by the parents. Improvements in speech were given by four out of the 
five parents. Of note, S-DR whose parents did not comment on improvements with 
speech did not begin with a speech delay. Improvements in affect/behavior were mostly 
noted by the child’s affect being happier, seeming to have fun. This was noted by two 
out of the five parents. Lastly, more alert and eye contact was noted by two out of the 
five parents.  
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Summary  
 In summary, as evidenced by the review, all four areas of question showed 
improvement after a two-month therapy. As an observational study a trend of 
improvement was being assessed. This trend was clearly achieved. There was a large 
difference in pretest and post test mean scores of the two groups. Although the t-test 
reveals there is not a consistent statistically significant difference once the differing 
variances of the two groups are taken into account, the small group size clearly was a 
determent in achieving significant scores between the pre and post test. In Chapter 5, a 
discussion of the findings and implications for the use of hyperbaric oxygen therapy with 
children diagnosed with autism will occur. Recommendations for further research and 
conclusions are presented as well. 
  107 
 
 
 
Chapter 5 
Summary and Discussion 
Purpose 
The purpose of the study was to obtain data on the efficacy of treating a child 
with autism in hyperbaric oxygen therapy by assessing changes in 
speech/language/communication, sociability, sensory/cognitive awareness, and 
health/physical/behavior. The study was designed with the knowledge that the small 
number of participants would not achieve statistically significant outcome, but rather the 
researcher was looking for a trend to show if there is efficacy in duplicating the study 
with a larger sample. A combination of qualitative and quantitative techniques was used 
for data analysis to assess the changes with participants who have autism. 
Autism is the fastest growing epidemic ever to occur in the world, with prevalence 
of 1 in 80 children by the age of 8 (MMWR/CDC 2009). According to the Data 
Accountability Center (DAC) and the Center for Disease Control (CDC), Michigan alone 
reported in 1992 1,180 cases of autism ages 6-22, by 2007 the number of reported 
cases went to 10,803, and 12,166 for ages 3-22. Children ages 6-22 had an increase of 
816%, in contrast all other disabilities combined only went up 35%. The costs of 
educating a child with autism are significant to the school systems and taxpayers as 
these children age and continue to increase in population. The CDC estimates the 
lifetime cost to care for an individual with autism to be 3.2 million dollars (Ganz 2007). 
Definition 
At the present day, according to the Center for Disease Control, Autism 
Spectrum Disorder (ASD) is an umbrella of disorders of developmental disabilities 
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identified by deficits in communication and social interactions; along with unusual, 
sometimes repetitive, behaviors; having areas of interest often with a narrow focus; and 
frequently an insistence on sameness. The cognitive abilities can vary from superior 
intelligence to mental impairment. ASD is found in all races, ethnic and socioeconomic 
levels.   
Rationale for study 
The study looked first at the etiology of autism and the physical effects it has on 
these children to assess the efficacy of treating a child with hyperbaric oxygen therapy. 
Three etiologies were researched: genetics, increase of diagnosing, and environmental 
toxin such as mercury or viral overload. The first two etiologies were found to have little 
to no evidence supporting them as a possible reason for the enormous increase in 
children with autism, on the contrary the evidence found those theories to be in error. 
The last possible cause, environmental, did have vast amounts of evidence correlating 
to the increase in autism.  
Next, research on the impact of the child physically in correspondence to 
environmental toxins was explored. Brain deficits in the area of 
hypoperfusion/decreased cerebral blood flow, reduction of the Purkinje cells, 
inflammation, and lack of synchronization is common findings in the research in the 
area of autism. These deficiencies are clearly linked to the deficits found in people with 
autism. Interestingly, neurological effects of mercury on the brain are in the amygdale, 
hippocampus, basal ganglia, cerebral cortex, damages Purkinje and granule cells in the 
cerebellum, paralleling the damage found in the autistic brain. 
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The neurological abnormalities manifest as deficits in cerebral blood flow, 
hypoperfusion, neuroinflammation, and lack of brain synchronization. The occurrence of 
inflammation in the brain and gastrointestinal tract of these children has also been 
shown to be significant. This is important to understand in order to begin to find ways to 
treat people with autism, and understand the theory behind the treatment. This is 
reflective in the treatment of hyperbaric oxygen therapy. When a person receives 
hyperbaric oxygen therapy the blood flow in the brain increases, it promotes the growth 
of new capillaries, increases the production of the body’s stem cells, decreases swelling 
and inflammation, increases the body’s ability to fight infections, and clears and 
deactivates toxins and metabolic waste products from the body.  Hence, hypoxia and 
inflammation are reduced resulting in reduction of negative symptoms listed above. 
Hence, it is reasonable to recognize how hyperbaric oxygen therapy may decrease 
neurological deficits and reduce symptoms of autism. Hyperbaric oxygen therapy may 
be one answer to addressing the neurological deficits in autism to be treatable.  
 Hyperbaric oxygen therapy is well known as an anti-inflammatory, and has 
virtually no negative side effects.  With the known effects of hyperbaric oxygen therapy 
and the inflammation found in children with autism, there warrants continued studies of 
treating children with autism in hyperbaric oxygen therapy. The risk-benefit analysis is 
strongly in favor of pursuing hyperbaric oxygen therapy as a potential therapy for 
autism. 
Aim of study and design 
The study aimed to ascertain the efficacy of a child with autism treating with 
hyperbaric oxygen therapy to lessen the negative effects of autism. The current 
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functioning level of the participants was scored by both a parent and teacher just prior to 
treatment and immediately following treatment with scores on the ATEC. The 
researcher also acquired qualitative data collected by the Certified Hyperbaric 
Technologist (CHT) and the parents.  
After IRB approval and participants were screened and accepted, the first step in 
the study was to verify interrater reliability between parent’s and teacher’s ATEC scores. 
Using Pearson correlation coefficient the pretest scores from the ATEC were compared. 
Both sets of scores were compared to explore the possibility of not needing to collect 
both sets of data for replicated studies in the future. The Pearson correlation coefficient 
measured the strength of a linear association between the pretest filled out by the 
parent to that filled out by the teacher. 
Results 
The correlations between parents and teachers on the ATEC were significant 
and provides support for interrater reliability. The implications for future studies would 
only suggest collecting data from parents; however, the teacher’s input on their 
perception on changes is very important in assessing the functioning improvements in 
the education of a child with autism.   
Some of the teachers were apprehensive completing the ATEC. The attitude of 
two of the teachers was pessimistic. One teacher called the researcher to exclaim, “The 
pre and post results will be the same as children won’t show any improvements with 
money wasting alternatives the parents are using.” Another teacher was resistant to fill 
out the information, fearing their name will somehow show up in the future, and didn’t 
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want to be any part of alternative therapies. These attitudes of the teachers could have 
skewed the results to not have them be as positive as they could have been.  
 The second step was to compare the pretest and post test scores of the child to 
assess for any changes in current level of performance. Although the small sample 
guaranteed low statistical power, the participants showed improvements in all areas. 
Even with low statistical power, sensory/cognitive awareness was statistically 
significant. The results of the ATEC reported a 14.29% change in the area of 
sensory/cognitive awareness of the participants. Another significant improvement was 
reported by the parents in the area of Health/Physical/Behavior with a 17.61% of 
improvement.  
Conclusions 
Children with autism can go months, even years, with little to no improvement in 
their functioning abilities. Teachers and parents alike celebrate little milestones as huge. 
A 17.61% improvement in the health and behavior and 14.29% sensory cognitive 
awareness of a child with autism is huge in the eyes of parents and teachers. These 
gains often give the child enough of a jump to continue to progress at a faster rate of 
improvement.  
Of interest to note is the largest areas of improvements differed from parents and 
teachers. Teachers, as would be expected, focused more on the cognitive growth, and 
that is the area they found the largest area of improvements in. On the other hand, 
parents saw behavior and health as the largest area of growth, the area they would be 
expected to see the most in a home environment.  
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The parent’s narrative agreed with the ATEC scores, commenting on the child 
eating better, calmer, sleeping better and interacting more with the parents and siblings. 
Improvements with the child’s sleep alone can offer the entire family great relief. Also, 
interaction with other, joint attention, improves their ability to absorbing information 
around them.  
The child in the study that showed the least amount of improvements was the 
only one with a questionable diagnosis of autism. The parents shared that a doctor told 
them their child was not autistic, rather cognitively impaired. The child is a twin; during 
gestation he received less nutrition and oxygen than his twin brother, weighing almost 
half his brother’s weight at birth. The school’s original diagnosis was cognitively 
impaired. Through much pressure from the parents, the school agreed to the label of 
autistic impaired. The parents conveyed they felt he would get a better education 
without a cognitively impaired label. The dad also expressed he too had a “mentally 
impaired” diagnosis during his schooling. This situation is an example of the difficulty of 
selecting a primary diagnosis with a child who has autism. Often children have a co-
morbidity of two or more conditions that go along with the autism. This child presented 
both as cognitively impaired and autistic.    
Research Questions 
The four questions in the study were all answered with affirmation of 
improvements. The data from the participants demonstrated improvement in all areas 
deficit listed in the questions below. 
Is there an increase in speech/language/communication of an autistic child who 
has received hyperbaric oxygen therapy using the Autism Treatment Evaluation 
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Checklist as a measurement tool?  The parents reported a 6.33 percentage of 
improvements and the teachers reported a 10.34 percentage of improvements in the 
area of speech/language/communication.  
Is there an increase in sociability of an autistic child who has received hyperbaric 
oxygen therapy using the Autism Treatment Evaluation Checklist as a measurement 
tool? The parents reported a 10.53 percentage of improvements and the teachers 
reported a 3.96 percentage of improvements in the area of sociability. 
Is there an increase in sensory/cognitive awareness of an autistic child who has 
received hyperbaric oxygen therapy using the Autism Treatment Evaluation Checklist as 
a measurement tool? The parents reported a 4.11 percentage of improvements and the 
teachers reported a 14.29 percentage of improvements in the area of sensory/cognitive 
awareness. 
Is there an increase in the health/physical/behavior of an autistic child who has 
received hyperbaric oxygen therapy using the Autism Treatment Evaluation Checklist as 
a measurement tool? The parents reported a 17.61 percentage of improvements and 
the teachers reported a 10.22 percentage of improvements in the area of 
health/physical/behavior. 
It is also interesting to note the children all enjoyed the treatment, requesting to 
go in as soon as they got to the center. Several parents stated they were able to get 
their child to dress independently for the first time with the reward being going into the 
hyperbaric chamber. 
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Conclusions and Implications 
 Taking in account the limitations of sample size, the study is suggesting the 
following: 
1. Children with autism do show a trend of improvement in speech/language, 
sociability, sensory/cognitive awareness and health/behavior when treating with 
hyperbaric oxygen therapy. 
2. Teacher and parents responses were statistically similar enough to warrant only 
collecting data from one in the future, although both inputs do show value. 
3. Further research could reveal more insight in the recovery of autism. 
Future Work  
Duplicating the study in the future with a larger sample size would give validation 
for the efficacy of treating children with autism in hyperbaric oxygen therapy. Another 
study could take children who have already done the forty treatments and assess if 
there is any continuation of improvements in treating the children with another set of 
forty treatments. Research combining other types of therapy such as gluten free diets or 
methyl-B 12 injections with hyperbaric oxygen therapy could also have justification.  
With the tremendous growth in the population of children with autism, and the 
financial impact it will have on society as these children age, not to mention the impact 
on the family, continual research is vital to one day find an effective treatment for 
autism. 
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APPENDIX A 
 
Michigan Rule 340.1715: Autism Spectrum Disorder Eligibility 
 
(1) Autism spectrum disorder is considered a lifelong developmental disability that adversely 
affects a student’s educational performance in 1 or more of the following performance areas: (a) 
Academic. (b) Behavioral. (c) Social. 
Autism spectrum disorder is typically manifested before 36 months of age. A child who first 
manifests the characteristics after age 3 may also meet criteria. Autism spectrum disorder is 
characterized by qualitative impairments in reciprocal social interactions, qualitative impairments 
in communication, and restricted range of interests/repetitive behavior. 
(2) Determination for eligibility shall include ALL of the following: 
(A) Qualitative impairments in reciprocal social interactions including at least 2 of the following 
areas: (i) Marked impairment in the use of multiple nonverbal behaviors such as eye-to-eye 
gaze, facial expression, body postures, and gestures to regulate social interaction. (ii) Failure to 
develop peer relationships appropriate to developmental level. 
(iii) Marked impairment in spontaneous seeking to share enjoyment, interests, or achievements 
with other people, for example, by a lack of showing, bringing, or pointing out objects of interest. 
(iv) Marked impairment in the areas of social or emotional reciprocity. 
(B) Qualitative impairments in communication including at least 1 of the following: (i) Delay in, or 
total lack of, the development of spoken language not accompanied by an attempt to 
compensate through alternative modes of communication such as gesture or mime. (ii) Marked 
impairment in pragmatics or in the ability to initiate, sustain, or engage in reciprocal 
conversation with others. (iii) Stereotyped and repetitive use of language or idiosyncratic 
language. (iv) Lack of varied, spontaneous make-believe play or social imitative play 
appropriate to developmental level. 
(C) Restricted, repetitive, and stereotyped behaviors including at least 1 of the following: (i) 
Encompassing preoccupation with 1 or more stereotyped and restricted patterns of interest that 
is abnormal either in intensity or focus. (ii) Apparently inflexible adherence to specific, 
nonfunctional routines or rituals. 
(iii) Stereotyped and repetitive motor mannerisms, for example, hand or finger flapping or 
twisting, or complex whole-body movements. 
(iv) Persistent preoccupation with parts of objects. 
(3) Determination may include unusual or inconsistent response to sensory stimuli, in 
combination with subdivisions (A), (B), and (C) of subrule 2 of this rule. 
(4) While autism spectrum disorder may exist concurrently with other diagnoses or areas of 
disability, to be eligible under this rule, there shall not be a primary diagnosis of schizophrenia or 
emotional impairment. 
(5) A determination of impairment shall be based upon a comprehensive evaluation by a 
multidisciplinary evaluation team including, at a minimum, a psychologist or psychiatrist, an 
authorized provider of speech and language under R 340.1745(d), and a school social worker. 
 
 
 
Rule Details for Autism Spectrum Disorder Eligibility Form (Michigan Revised Special Education 
Rules - Sept. 2004) 
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APPENDIX B 
 
Dave Weldon, M.D. 
15th District, Florida 
Congress of the United States 
House of Representatives 
Washington DC 20515  
October 31, 2003  
Julie L. Gerberding, M.D., M.P.H. 
Director, Centers for Disease Control and Prevention 
1600 Clifton Road, N.E. 
Atlanta, GA 30333  
Dear Dr. Gerberding:  
I am writing to follow up on our conversation about the article (Verstraeten et. al.,) that will be published in 
the November 2003 issue of Pediatrics. I have reviewed the article and have serious reservations about 
the four-year evolution and conclusions of this study.  
Much of what I observed transpired prior to your appointment a year ago as the Director of the Centers 
for Disease Control and Prevention (CDC). I am very concerned about activities that have taken place in 
the National Immunization Program (NIP) in the development of this study, and I believe the issues raised 
need your personal attention.  
I am a strong supporter of childhood vaccinations and know that they have saved us from considerable 
death and suffering. A key part of our vaccination program is to ensure that we do everything possible to 
ensure that these vaccines, which are mandatory, are as safe as possible. We must fully disclose 
adverse events. Anything less than this undermines public confidence.  
I have read the upcoming Pediatrics study and several earlier versions of this study dating back to 
February 2000. I have read various e-mails from Dr. Verstraeten and coauthors. I have reviewed the 
transcripts of a discussion at Simpsonwood, GA between the author, various CDC employees, and 
vaccine industry representatives. I found a disturbing pattern which merits a thorough, open, timely, and 
independent review by researchers outside of the CDC, HHS, the vaccine industry, and others with a 
conflict of interest in vaccine related issues (including many in University settings who may have 
conflicts).  
A review of these documents leaves me very concerned that rather than seeking to understand whether 
or not some children were exposed to harmful levels of mercury in childhood vaccines in the 1990s, there 
may have been a selective use of the data to make the associations in the earliest study disappear. While 
most childhood vaccines now only have trace amounts of mercury from thimerosal containing vaccines 
(TCVs), it is critical that we know with certainty if children were injured in the 1990s.  
Furthermore, the lead author of the article, Dr. Thomas Verstraeten, worked for the CDC until he left over 
two years ago to work in Belgium for GlaxoSmithKline (GSK), a vaccine manufacturer facing liability over 
TCVs. In violation of their own standards of conduct, Pediatrics failed to disclose that Dr. Verstraeten is 
employed by GSK and incorrectly identifies him as an employee of the CDC. This revelation undermines 
this study further.  
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The first version of the study, produced in February 2000, found a significant association between 
exposure to thimerosal containing vaccines (TCVs) and autism and neurological developmental delays 
(NDDs). When comparing children exposed to 62.5 ug of mercury by 3 months of age to those exposed 
to less than 37.5 ug, the study found a relative risk for autism of 2.48 for those with a higher exposure 
level. (While not significant in the 95% confidence interval for autism, this meets the legal standard of 
proof exceeding 2.0.) For NDDs the study found a relative risk of 1.59 and a definite upward trend as 
exposure levels increased.  
A June 2000 version of the study applied various data manipulations to reduce the autism association to 
1.69 and the authors went outside of the VSD database to secure data from a Massachusetts HMO 
(Harvard Pilgrim, HP) in order to counter the association found between TCVs and speech delay. At the 
time that HP's data was brought in, HP was in receivership by the state of Mass., its computer records 
had been in shambles for years, it had multiple computer systems that could not communicate with one 
another (Journal of Law, Ethics and Medicine Sept. 22, 2000), and it used a health care coding system 
totally different from the one used across the VSD. There are questions relating to a significant 
underreporting of Autism in Mass. The HP dataset is only about 15% of the HMO dataset used in the 
February 2000 study. There may also be significant problems with the statistical power of the HP dataset.  
In June of 2000 a meeting was held in Simpsonwood, GA, involving the authors of the study, 
representatives of the CDC, and the vaccine industry. I have reviewed a transcript of this meeting that 
was obtained through the Freedom of Information Act (FOIA). Comments from Simpsonwood, NJ meeting 
include: (summary form, not direct quotes):  
* We found a statistically significant relationship between exposures and outcomes. There is certainly an 
under ascertainment of adverse outcomes because some children are just simply not old enough to be 
diagnosed, the current incidence rates are much lower than we would expect to see (Verstraeten);  
* We could exclude the lowest exposure children from our database. Also suggested was removing the 
children that got the highest exposure levels since they represented an unusually high percentage of the 
outcomes. (Rhodes)  
* The significant association with language delay is quite large. (Verstraeten);  
* This information should be kept confidential and considered embargoed;  
* We can push and pull this data anyway we want to get the results we want;  
* We can alter the exclusion criteria any way we want, give reasonable justifications for doing so, and get 
any result we want;  
* There was really no need to do this study. We could have predicted the outcomes;  
* I will not give TCVs to my grandson until I find out what is going on here.  
Another version of the study - after further manipulation - finds no association between TCVs and autism, 
and no consistency across HMOs between TCVs and NDDs and speech delay.  
The final version of the study concludes that "No consistent significant associations were found between 
TCVs and neurodevelopmental outcomes," and that the lack of consistency argues against an 
association. In reviewing the study there are data points where children with higher exposures to the 
neuortoxin mercury had fewer developmental disorders. This demonstrates to me how excessive 
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manipulation of data can lead to absurd results. Such a conclusion is not unexpected from an author with 
a serious, though undisclosed, conflict of interest.  
This study increases speculation of an association between TCVs and neurodevelopmental outcomes. I 
cannot say it was the author's intent to eliminate the earlier findings of an association. Nonetheless, the 
elimination of this association is exactly what happened and the manner in which this was achieved 
raises speculation. The dialogue at the Simpsonwood meeting clearly indicates how easily the authors 
could manipulate the data and have reasonable sounding justifications for many of their decisions.  
The only way these issues are going to be resolved - and I have only mentioned a few of them - is by 
making this particular dataset and the entire VSD database open for independent analysis. One such 
independent researcher, Dr. Mark Geier, has already been approved by the CDC and the various IRBs to 
access this dataset. They have requested the CDC allow them to access this dataset and your staff 
indicated to my office that they would make this particular dataset available after the Pediatrics study is 
published.  
Earlier this month the CDC had prepared three similar datasets for this researcher to review to allow him 
to reanalyze CDC study datasets. However when they accessed the datasets - which the researchers 
paid the CDC to assemble - the datasets were found to have no usable data in them. I request that you 
personally intervene with those in the CDC who are assembling this dataset to ensure that they provide 
the complete dataset, in a usable format, to these researchers within two weeks. The treatment that these 
well-published researchers have received from the CDC thus far has been abysmal and embarrassing. I 
would also be curious to know whether Dr. Verstraeten, an outside researcher for more than two years 
now, was required to go through the same process as Dr. Geier in order to continue accessing the VSD.  
You have not been a part of creating this current situation, but you do have an opportunity to help resolve 
this issue and ensure that confidence and trustworthiness in the CDC and our national vaccination 
program is fully restored. I would ask that you work with me to ensure that a full, fair, and independent 
review is made of the VSD database to fully examine this matter. I would like to meet with you at your 
earliest convenience to move this process forward.  
Thank you for your consideration. I look forward to working with you on this urgent matter of great 
importance to our nation's most precious resource, our children.  
Sincerely, 
Dave Weldon, M.D. 
Member of Congress 
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APPENDIX D 
Questionnaire for parents of prospective participant: 
 
1. Date of Birth: __________________________ 
2. Does the child have a school eligibility to receive services in the area of autism?   
3. Has the school conducted a Multi- Disciplinary Evaluation Team (MET) to 
determine eligibility? When/age? 
4. Does the child have an IEP?  
5. Would you agree to have your child be part of a research study? 
6. Would you agree to let me contact your child’s teacher to see if he or she would 
be willing to participate in the study by filling out a pre and post evaluation 
regarding your child?  
7. Has the child ever participated in hyperbaric oxygen therapy?  
8. Can the parent/caretaker provide written consent to be part of the study? 
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APPENDIX E 
Summary of the Data 
Range of scores 
ATEC scores range from zero to 180. The lower the score, the better.  
If a child scores zero or close to zero, that child cannot be distinguished from other 
normal children. He or she can be considered fully recovered and not autistic.  
The important benchmarks in scoring are as follows:  
• ATEC < 30. This level places the child in the top 10 percentile. A child with score 
of less than 30 – or, better still, less than 20 – would have some ability to conduct 
normal, two-way conversations, and more or less behave normally. Such children 
have high chances of leading normal lives as independent individuals. 
 
• ATEC < 50. This places the child in the 30th percentile level. The child has good 
chances of being semi-independent. More importantly, he or she will not likely 
need to be placed in an institution. For many parents of autistic children, being 
able to achieve improvement up to this level is already considered very 
significant. 
ATEC > 104. Even though the maximum score is 180, any person with a score of 
more than 104 would already be in the 90th percentile, and be considered very 
severely autistic. 
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APPENDIX F 
Sample test scoring from ATEC 
Date: 11/2/2010 2:11:15 PM 
Child's Name: Student Test 
------------------------------------------------------------------- 
***TOTAL AND SUBSCALE SCORES*** 
Total Score: 131 
I. Speech/Language/Communication: 24 
II. Sociability: 36 
III. Sensory/Cognitive Awareness: 32 
IV. Health/Physical/Behavior: 39 
------------------------------------------------------------------- 
------------------------------------------------------------------- 
I. Speech/Language/Communication 
1. Knows own name: Somewhat true 
2. Responds to `No' or `Stop': Somewhat true 
3. Can follow some commands: Somewhat true 
4. Can use one word at a time: Somewhat true 
5. Can use 2 words at a time: Not true 
6. Can use 3 words at a time: Not true 
7. Knows 10 or more words: Not true 
8. Can use sentences with 4 or more words: Not true 
9. Explains what he/she wants: Not true 
10. Asks meaningful questions: Not true 
11. Speech tends to be meaningful/relevant: Not true 
12. Often uses several successive sentences: Not true 
13. Carries on fairly good conversation: Not true 
14. Has normal ability to com municate for his/her age: Not true 
----------- 
Total for Section I: 24 
------------------------------------------------------------------- 
------------------------------------------------------------------- 
**II. Sociability 
1. Seems to be in a shell - you cannot reach him/her: Very descriptive 
2. Ignores other people: Very descriptive 
3. Pays little or no attention when addressed: Somewhat descriptive 
4. Uncooperative and resistant: Somewhat descriptive 
5. No eye contact: Very descriptive 
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6. Prefers to be left alone: Very descriptive 
7. Shows no affection: Very descriptive 
8. Fails to greet parents: Very descriptive 
9. Avoids contact with others: Very descriptive 
10. Does not imitate: Very descriptive 
11. Dislikes being held/cuddled: Somewhat descriptive 
12. Does not share or show: Very descriptive 
13. Does not wave `bye bye': Very descriptive 
14. Disagreeable/not compliant: Very descriptive 
15. Temper tantrums: Somewhat descriptive 
16. Lacks friends/companions: Very descriptive 
17. Rarely smiles: Very descriptive 
18. Insensitive to other's feelings: Very descriptive 
19. Indifferent to being liked: Very descriptive 
20. Indifferent if parent(s) leave: Very descriptive 
----------- 
Total for Section II: 36 
------------------------------------------------------------------- 
------------------------------------------------------------------- 
III. Sensory/Cognitive Awareness 
1. Responds to own name: Somewhat descriptive 
2. Responds to praise: Somewhat descriptive 
3. Looks at people and animals: Not descriptive 
4. Looks at pictures (and T.V.): Somewhat descriptive 
5. Does drawing, coloring, art: Not descriptive 
6. Plays with toys appropriately: Not descriptive 
7. Appropriate facial expression: Not descriptive 
8. Understands stories on T.V.: Not descriptive 
9. Understands explanations: Not descriptive 
10. Aware of environment: Not descriptive 
11. Aware of danger: Not descriptive 
12. Shows imagination: Somewhat descriptive 
13. Initiates activities: Not descriptive 
14. Dresses self: Not descriptive 
15. Curious, interested: Not descriptive 
16. Venturesome - explores: Not descriptive 
17. Tuned in - Not spacey: Not descriptive 
18. Looks where others are looking: Not descriptive 
------------ 
Total for Section III: 32 
------------------------------------------------------------------- 
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------------------------------------------------------------------- 
IV. Health/Physical/Behavior 
1. Bed-wetting: Minor Problem 
2. Wets pants/diapers: Minor Problem 
3. Soils pants/diapers: Not a Problem 
4. Diarrhea: Moderate Problem 
5. Constipation: Moderate Problem 
6. Sleep problems: Serious Problem 
7. Eats too much/too little: Minor Problem 
8. Extremely limited diet: Serious Problem 
9. Hyperactive: Moderate Problem 
10. Lethargic: Minor Problem 
11. Hits or injures self: Minor Problem 
12. Hits or injures others: Minor Problem 
13. Destructive: Minor Problem 
14. Sound-sensitive: Serious Problem 
15. Anxious/fearful: Moderate Problem 
16. Unhappy/crying: Minor Problem 
17. Seizures: Not a Problem 
18. Obsessive speech: Minor Problem 
19. Rigid routines: Moderate Problem 
20. Shouts or screams: Minor Problem 
21. Demands sameness: Moderate Problem 
22. Often agitated: Moderate Problem 
23. Not sensitive to pain: Minor Problem 
24. Hooked or fixated on certain objects/topics: Moderate Problem 
25. Repetitive movements: Serious Problem 
------------- 
Total for Section IV: 39 
------------------------------------------------------------------- 
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APPENDIX G 
Dive Log documented notes and observations: 
T-TW 
1) 2/14/2011 – T-TW very upset yelling and kicking 1st ten minutes of tx. To 2.0 
ata 
2) 2/15/2011 - T-TW more relaxed – to 2.0 ata 
3) 2/16/2011 - 2.0 ata – nothing remarkable 
4) 2/17/2011 - 2.0 ata 
5) 2/18/2011 – T-TW is more calm, relaxed and attentive - 2.0 ata 
6) 2/23/2011 - 2.0 ata 
7) 2/28/2011 - 2.0 ata – T-TW much better. Behavior, calmer, playful, joyful 
8) 3/01/2011 - 2.0 ata 
9) 3/02/2011 - 2.0 ata 
10) 3/03/2011 - more smiles, focus and conversation 
11) 3/04/2011 - 2.0 ata 
12) 3/07/2011 – T-TW calm, relaxed entire time. Very good mood – 2.0 ata 
13) 3/08/2011 - 2.0 ata 
14) 3/10/2011 – T-TW is more alert. Great kid. 2.0 ata 
15) 3/11/2011—2.0 ata 
16) 3/15/2011- 2.0 ata 
17) 3/16/2011- 2.0 ata 
18) 3/17/2011 – pre dad: T-TW pays attention more when asked to do something. 
2.0 ata 
19) 3/18/2011 – was screaming, then calmed down, had bad day. 2.0 ata 
20) 3/21/2011 - 2.0 ata 
21) 3/25/2011 - 2.0 ata 
22) 3/28/2011 - 2.0 ata 
23) 3/30/2011 - 2.0 ata 
24) 3/31/2011 - 2.0 ata 
25) 4/1/2011 - 2.0 ata 
26) 4/11/2011 - 2.0 ata 
27) 4/12/2011 – was screaming, then calmed down. Out of routine, spring break. 
2.0 ata 
28) 4/13/2011 – same as dive 27. 2.0 ata 
29) 4/14/2011 – seemed calmer. 2.0 ata 
30) 4/15/2011 – seemed calmer. 2.0 ata 
31) 4/18/2011 – calm 2.0 ata 
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32) 4/19/2011 – calm 2.0 ata 
33) 4/21/2011 - 2.0 ata 
34) 4/22/2011 - 2.0 ata 
35) 4/25/2011 – good day, watching cars go by when blinds were opened. 2.0 ata 
36) 4/26/2011 – good day, watched cars go by 2.0 ata 
37) 4/27/2011 – good day, watched cars go by 2.0 ata 
38) 4/28/2011 – good day 2.0 ata 
39) 4/29/2011 – good day 2.0 ata 
40) 5/2/2011 – good day 2.0 ata 
 
3/30/2011—note from mom 
As of today, Wednesday March 30, 2011, my son, T-TW has completed 23 “dives.” We 
looked into this treatment for his Autism Spectrum Disorder. Before the “dives” one of 
the behaviors T-TW had was an indifference to people and things around him. Since the 
“dives” he has shown more interest in people, to the point of at least acknowledging a 
stranger by glancing at them and especially in new “things” presented to him. The other 
significant improvement has been with his comprehension. Before the Hyperbaric 
Oxygen Therapy, if or when, we told T-TW to do something, he wouldn’t or couldn’t. As 
if he didn’t understand what he was being asked of him. Now he is following simple one-
step commands consistently and some two-step commands as well. As an added 
benefit, we also are seeing more speech. He does receive speech therapy at school 
and independently at an outside facility, but besides just being able to “speak” or say 
the words, he is using the speech appropriately and in context. I am eager to see our 
results after completing all 40 “dives.”  (K. W., mother) 
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T-JC.  
Dive Log documented notes and observations: 
1) 2/14/2011 - Great 1st tx. T-JC sweated profusely. 2.0 ata (Playing with fridge 
magnets. Spelled, “welcome harry potter” playing with our dog better. Also 
saying,  “come here Rio.”) 
2) 2/15/2011 – T-JC was toe-walking but excited to tx. 2.0 ata (Going into 
chamber said, “come on let’s go in.”) 
3) 2/16/2011 - 2.0 ata  T-JC eager to start (Jumpy in chamber. Playful and 
talking about movie) 
4) 2/17/2011 - 2.0 ata T-JC sweating and yelling, almost Tourette like to stim. 
(Jumpy in chamber) 
5) 2/18/2011 - 2.0 ata  (Jumpy in chamber) 
6) 2/19/2011—(Said “hey, where’s Luke” when Luke was in bathroom.) 
7) 2/20/2011—(Eating better. Saying prayers slower, not as hyper, loving, 
playful and not yelling as much.) 
8) 2/21/2011 - 2.0 ata Dad said they are please with T-JC improvements. 
(Jumpy in chamber, eating good, poops a lot. Went out to lunch and did best 
ever in a restaurant.) 
9) 2/22/2011 (no HBOT due to ice. Eating good. Talking good.) 
10) 2/23/2011 (no HBOT due to ice. Eating good.) 
11) 2/24/2011 - 2.0 ata – very vocal. Lots of yelling (playing good with Rio and 
Luke. Jumpy in chamber) 
12) 2/25/2011 - 2.0 ata (Worse ever in chamber) 
13) 2/26/2011 (playing good) 
14) 2/27/2011 (T-JC had runs bad in morning) 
15) 2/28/2011 (Prayers slower and using L**’s DS first time ever. Hand held video 
games. Playing with my calculator.) 
16) 3/01/2011 - 2.0 ata – very vocal (same)  
17) 3/02/2011 - 2.0 ata – saw Dr. **** for blood test, said he is weird (same) 
18) 3/03/2011 - 2.0 ata – verbal (same) 
19) 3/04/2011 - 2.0 ata – verbal (eating good. Good in chamber. Playing with 
more and more. Still playing DS. Harder poop. Kissing a lot. Asked for horsey 
ride. When I put him down he said, “come on you can do it.” First 6 word 
sentence. Saying “Hi” to people at Kroger’s.) 
20) 3/05/2011 (Playing good with R** and L**. Comes up and hugs without me 
asking for it. Hung up towel after using in bathroom. Harder poop. Pee stinks 
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bad. Helped me make chicken soup for first time. Using squirt gun shooting 
L*** saying, “got you.”) 
21) 3/6/2011 (level day) 
22) 3/07/2011 - 2.0 ata – verbal for seemingly attention (level day) 
23) 3/08/2011 - 2.0 ata - dad cannot control verbal outburst. (level day) 
24) 3/09/2011 – 2.0 ata (level day) 
25) 3/10/2011 (iced in, no HBOT. Jumped on for horsey ride and said got ya) 
26) 3/11/2011 (iced in, no HBOT.) 
27) 3/13/2011 (good day) 
28) 3/14/2011 – 2.0 ata (bad in chamber, pee still stinks) 
29) 3/15/2011 – 2.0 ata (in chamber said “almost done. Five more minutes.”) 
30) 3/16/2011 – 2.0 ata (less babbling each day.) 
31) 3/17/2011 – 2.0 ata (looking at people more each day.) 
32) 3/18/2011 – 2.0 ata (Pointed to door and said, “R** poop outside.” Wanted me 
to let him out. Reading all color words correctly. Playing with magnets on 
fridge and spelling words out. He asked me to write seven people from DVD 
on marker board and pointed to and told me all names correctly.) 
33) 3/19/2011 (Opened door without anyone telling him to when I came home and 
said “hi daddy.” Dropped a lot of papers on ground and said, “somebody 
broke that.” Asks for paper and markers daily.  
34) 3/20/2011 (Playing good with R** and L*** and helped with burning leaves 
outside. 
35) 3/21/2011 (iced in, no HBOT No yelling out hardly at all.)  
36) 3/22/2011 – 2.0 ata 
37) 3/28/2011 – 2.0 ata T-JC doing well! No yelling! 
38) 3/29/2011 – 2.0 ata 
39) 3/30/2011 – 2.0 ata T-JC calmer, less yelling, more eye contact 
40) 4/01/2011– 2.0 ata T-JC doing well 
41) 4/04/2011 – 2.0 ata 
42) 4/05/2011 – 2.0 ata 
43) 4/06/2011 – 2.0 ata 
44) 4/07/2011 – 2.0 ata 
45) 4/08/2011 – 2.0 ata  
46) 4/11/2011 – 2.0 ata 
47) 4/12/2011 – 2.0 ata 
48) 4/13/2011 – 2.0 ata 
49) 4/14/2011 – 2.0 ata 
50) 4/15/2011 – 2.0 ata 
51) 4/18/2011  – 2.0 ata 
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52) 4/19/2011 – 2.0 ata 
53) 4/20/2011 – 2.0 ata 
54) 4/21/2011 – 2.0 ata 
55) 4/22/2011 – 2.0 ata 
T-SC 
Dive Log documented notes and observations: 
1) 1/31/2011 - didn’t relax until half-point of dive. Only to 1.4 ata 
2) 2/01/2011 - More relaxed 2.0 ata 
3) 2/03/2011 - 2.0 ata 
4) 2/04/2011 - 2.0 ata 
5) 2/07/2011 - 2.0 ata 
6) 2/08/2011 – 2.0 ata 
7) 2/09/2011 - 2.0 ata  
8) 2/10/2011 - stop for pressure in ears – dive at 1.75 ata 
9) 2/11/2011 - 1.75 ata 
10) 2/14/2011 – T-SC more attentive and alert – to 2.0ata 
11) 2/15/2011 - 2.0 ata 
12) 2/16/2011 - stopped for ears to 2.0 ata 
13) 2/17/2011 – T-SC more attentive and relaxed – to 2.0 ata 
14) 2/18/2011 - 2.0 ata 
15) 2/21/2011 - 2.0 ata 
16) 2/22/2011 - 2.0 ata 
17) 2/23/2011 – T-SC, according to mom, is more focused. 2.0 ata 
18) 2/24/2011 - 2.0 ata 
19) 2/25/2011 – T-SC with mom, calm. Mom says T-SC pays attention more at 
home. 2.0 ata 
20) 2/29/2011 - 2.0 ata 
21) 3/01/2011 - more attention, focus and conversation 2.0 ata 
22) 3/02/2011 - 2.0 ata 
23) 3/03/2011 - more smiles, focus and conversation 2.0 ata 
24) 3/04/2011 - 2.0 ata 
25) 3/07/2011 - 2.0 ata. No problem with ears. 
26) 3/08/2011 – 2.0 ata Manually clear 3x’s then T-SC had to use restroom, 
brought up 13 minutes early 
27) 3/09/2011 - 2.0 ata – no problem 
28) 3/10/2011 - 2.0 ata. Dad said she speaking clearer and communicates better 
29) 3/11/2011 – 2.0 ata  
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30) 3/14/2011 – 2.0 ata 
31) 3/15/2011 – 2.0 ata 
32) 3/16/2011 – 2.0 ata 
33) 3/17/2011 – 2.0 ata 
34) 3/18/2011 – 2.0 ata 
35) 3/21/2011 – 2.0 ata 
36) 3/22/2011 – 2.0 ata 
37) 3/23/2011 – 2.0 ata 
38) 3/25/2011 – 2.0 ata 
39) 3/28/2011 – 2.0 ata 
40) 3/30/2011 – 2.0 ata 
 
So far, we have observed the following changes in T-SC since she began HBOT: 
  
  Increase in independent behavior (saying “no” she doesn’t want to do this or that, she 
wants to do what she wants), since she never really went through this stage, this is 
probably a good thing.   
  
Some increase in eye contact, including looking at people while smiling (which she did 
not really do before) 
 
Increase in focus – she will spend a little longer with things like homework, puzzles, etc 
(maybe 4-6 minutes) 
  
Willingness to try to figure things out (kind of goes along with increased focus) she will 
attempt to do things that she was really resistant to trying before like puzzles, singing 
songs, etc. 
  
She is also showing an interest in new things like computer games – she will play with a 
computer (she’s had since she was 2, so it’s for very young children) and continue 
playing the letter game for up to 15 minutes. 
  
Also, as I stated earlier we will be happy to complete any additional surveys after a 
month or so and I’m sure her teacher will too. 
 
Thanks again for all of your help and advice! 
 
D C, mother 
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T-AO 
Dive Log documented notes and observations: 
1) 2/21/2011 - 2.0 ata  
2) 2/22/2011 - 2.0 ata  
3) 2/23/2011 - 2.0 ata.T- AO relaxed in chamber 
4) 2/24/2011 - 2.0 ata  Dad says T-AO much calmer at home and less temper 
5) 2/25/2011 - 2.0 ata  T-AO is relaxed and watched entire movie 
6) 2/28/2011 - 2.0 ata  Had trouble with descent. Leveled at 3 psi. Dad stated, 
“able to sleep at night after the very first dive. She was not sleeping before. 
She slept all night long. No tantrums with her coat. Wanted into chamber. 
More assertive.”  
7) 3/01/2011 - 2.0 ata  
8) 3/02/2011 - 2.0 ata   
9) 3/03/2011 - 2.0 ata – T-AO much calmer, no longer plays rough or climbing 
the walls. “T-AO is no longer climbing the walls and pulling cabinet doors off 
the hinges. No longer plays as rough, less bruises on her legs.) 
10) 3/04/2011 – T-AO relaxed and watched movie. Dad had trouble w/ears – level 
to 1.5 ata 
11) 3/07/2011 - 2.0 ata – no problems 
12) 3/09/2011 – T-AO feeling good! 2.0 ata 
13) 3/10/2011 - 2.0 ata  
14) 3/11/2011 – 2.0 ata 
15) 3/14/2011 – 2.0 ata 
16) 3/15/2011 – 2.0 ata 
17) 3/16/2011 – 2.0 ata 
18) 3/17/2011 – 2.0 ata 
19) 3/18/2011 – 2.0 ata 
20) 3/21/2011 – 2.0 ata 
21) 3/22/2011 – 2.0 ata 
22) 3/23/2011 – 2.0 ata 
23) 3/24/2011 – 2.0 ata 
24) 3/25/2011 – 2.0 ata 
25) 3/28/2011 – 2.0 ata 
26) 3/30/2011 – 2.0 ata 
27) 3/31/2011 – 2.0 ata 
28) 4/1/2011 – 2.0 ata 
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29) 4/4/2011 – 2.0 ata 
30) 4/5/2011 – 2.0 ata 
31) 4/6/2011 – 2.0 ata. According to mom: T-AO eating and sleeping better. In 
better mood. 
32) 4/8/2011 – 2.0 ata 
33) 4/11/2011 – 2.0 ata According to Dad, “her eating is back to normal, sleeping 
back to normal, no waking up, teacher said she said her name, she has a 
comprehension of emotion and mimics from the DVD. 
34) 4/12/2011 – 2.0 ata 
35) 4/13/2011 – 2.0 ata. According to dad, T-AO is taking in her own language. 
36) 4/14/2011 – 2.0 ata 
37) 4/18/2011 – 2.0 ata. According to dad, is now singing. “She ate 3 pieces of 
chicken (thighs) and potatoes, her appetite has increased. She is trying to say 
words. She is saying “so ki” for name. Her very strong personality is coming 
out. If she wants to do something, she stands firm on it.” 
38) 4/19/2011 – 2.0 ata 
39) 4/20/2011 – 2.0 ata According to dad, T-AO is mimicking/repeating words that 
you say. 
40) 4/22/2011 – 2.0 ata  
S-DR: 
Dive Log documented notes and observations: 
1) 2/21/2011 - 1.5 ata – congestion/coughing.  
2) 2/22/2011 - 1.5 ata – still congested 
3) 2/23/2011 - 1.5 ata – still congested 
4) 2/24/2011 - 1.75 ata 
5) 2/25/2011 – 1.75 ata 
6) 2/28/2011 – 1.75 ata 
7) 3/01/2011 – 1.75 ata 
8) 3/02/2011– 1.75 ata 
9) 3/03/2011– 1.75 ata 
10) 3/04/2011– 1.75 ata 
11) 3/07/2011– 1.75 ata 
12) 3/08/2011– 1.75 ata 
13) 3/09/2011– 1.75 ata 
14) 3/10/2011– 1.75 ata 
15) 3/11/2011– 1.75 ata 
16) 3/14/2011– 1.75 ata 
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17) 3/15/2011– 1.75 ata 
18) 3/16/2011– 1.75 ata 
19) 3/17/2011– 1.75 ata 
20) 3/18/2011– 1.75 ata 
21) 3/22/2011– 1.75 ata  congestion and coughing gone 
22) 3/23/2011 – 2.0 ata  
23) 3/24/2011– 2.0 ata 
24) 3/25/2011– 2.0 ata tech notes S-DR seems to be engaging visually and a little 
more attentive 
25) 3/26/2011– 2.0 ata 
26) 3/28/2011– 2.0 ata 
27) 3/29/2011– 2.0 ata  tech notes: He is more attentive, seems to be more engaging 
to others here at the clinic. (According to Dad, S-DR has been more relaxed for a 
week or so. Attending church has been more pleasant as S-DR has been 
calmer.) 
28) 3/30/2011– 2.0 ata 
29) 3/31/2011– 2.0 ata 
30) 4/01/2011– 2.0 ata 
31) 4/04/2011– 2.0 ata 
32) 4/05/2011– 2.0 ata 
33) 4/06/2011– 2.0 ata 
34) 4/07/2011– 2.0 ata 
35) 4/08/2011– 2.0 ata 
36) 4/11/2011– 2.0 ata 
37) 4/12/2011– 2.0 ata 
38) 4/13/2011– 2.0 ata 
39) 4/14/2011– 2.0 ata 
40) 4/15/2011– 2.0 ata 
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Autism is the fastest growing disability ever. With the growth comes a lot of 
questions as to the etiologies and treatment of this condition, often putting parents, 
schools, and traditional medical personnel at odds with what treatments have efficacy. 
As the popularity of alternative treatments increase, so does the need for research. 
Hyperbaric oxygen therapy is one alternative treatment parents are seeking for their 
child with autism. When one looks at the science behind hyperbaric oxygen therapy and 
the physical condition of a child with autism the rationale behind the treatment becomes 
clear. Research has shown that children with autism have decreased cerebral blood 
flow, neurological and gastrointestinal inflammation, reduction of purkinje cells, poor 
immune systems, increase of heavy metals, and deficits with their myelination. When 
these conditions are compared to the benefits one receives in hyperbarics a correlation 
is noted, and an understanding of why a child functioning improves.  
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This research was a study of five children with school diagnosis of autism that were 
doing hyperbaric oxygen therapy. Both the parents and the child’s teacher filled out a 
pre and post evaluation of the child using ATEC evaluation tool. The evaluation tool 
assessed improvements in the area of speech/language/communication, sociability, 
sensory/cognitive awareness, health/physical/behavior of a child with autism.The results 
were assessed with the SPSS (Statistical Package for the Social Sciences Personal 
Computer) software using  t-test with Paired Samples Statistics data analysis to 
compare the pretest and post test scores.  
All areas showed improvements. In speech/language/communication the parents 
reported a 6.33 percentage of improvements and the teachers reported a 10.34 
percentage of improvements. In sociability the parents reported a 10.53 percentage of 
improvements and the teachers reported a 3.96 percentage of improvements. In 
sensory/cognitive awareness the parents reported a 4.11 percentage of improvements 
and the teachers reported a 14.29 percentage of improvements. Lastly, in 
health/physical/behavior the parents reported a 17.61 percentage of improvements and 
the teachers reported a 10.22 percentage of improvements. 
Overall, the study concluded that further research with a larger sample size is 
warranted to see if hyperbaric oxygen therapy can help benefit children with autism.  
Key words: autism, hyperbaric oxygen therapy, alternative therapy, complementary 
therapy 
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